

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Voices from low-and-middle-income countries: a systematic review protocol of primary health care interventions within public health systems addressing intimate partner violence against women

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019266
Article Type:	Protocol
Date Submitted by the Author:	21-Aug-2017
Complete List of Authors:	Signorelli, Marcos; Universidade Federal do Parana, Collective Health Hillel, Stav; La Trobe University - Melbourne Campus, Library de Oliveira, Daniel; Universidade Federal do Rio Grande do Sul, Collective Health Ayala Quintanilla, Beatriz; La Trobe University College of Science Health and Engineering, Judith Lumley Centre; Peruvian National Institute of Health, Lima Hegarty, Kelsey; University of Melbourne, Dept of General Practice; The Royal Women's Hospital Taft, Angela; La Trobe University, Mother and Child Health Research
Primary Subject Heading:	Public health
Secondary Subject Heading:	Health services research, General practice / Family practice
Keywords:	PUBLIC HEALTH, INTIMATE PARTNER VIOLENCE, LOW-AND-MIDDLE-INCOME COUNTRIES, PRIMARY CARE, SYSTEMATIC REVIEW

SCHOLARONE™
Manuscripts

Title: Voices from low-and-middle-income countries: a systematic review protocol of primary health care interventions within public health systems addressing intimate partner violence against women

Authors:

1. Signorelli, MC.

Ph.D in Public Health

Postdoctoral Fellow, La Trobe University

Lecturer, Federal University of Parana

Rua Jaguariaíva, 512. Matinhos/PR - Brazil

T:+55 41 3511 8326

E: signorelli.marcos@gmail.com

2. Hillel, S.

Senior Learning Advisor (Library), La Trobe University

Plenty Road & Kingsbury Drive, Bundoora VIC 3086

T: 03 9479 6097

E: s.hillel@latrobe.edu.au

3. Oliveira, DC.

PhD in Health Sciences

Lecturer, Federal University of Rio Grande do Sul

Porto Alegre/RS, Brazil

T: +55 51 98344 5848

E: daniel.canavese@gmail.com

4. Ayala Quintanilla, BP.

Ph.D. candidate, Judith Lumley Centre, La Trobe University

Melbourne/VIC, Australia

T: 03 9479 8784

E: 17801497@students.latrobe.edu.au

5. Hegarty K,

Ph.D in Preventive Medicine

Professor of Family Violence Prevention, The Royal Women's Hospital, Melbourne

Professor, Department of General Practice, The University of Melbourne

Melbourne/VIC, Australia

E: k.hegarty@unimelb.edu.au

6. Taft A.

Ph.D in Public Health

1
2
3 Professor, Judith Lumley Centre, La Trobe University

4 Melbourne/VIC, Australia

5
6 E: a.taft@latrobe.edu.au
7

8
9 Word count: 4498 (excluding title, abstract, strengths & limitations, references and appendixes)
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Intimate partner violence (IPV) considerably harms the health, safety, and wellbeing of women. In response, public health systems around the globe have been gradually implementing strategies. In particular, low- and middle-income countries (LMIC) have been developing innovative interventions in primary health care (PHC) addressing the problem. This paper describes a protocol for a systematic review of studies addressing the impacts/outcomes of PHC centre interventions addressing IPV against women from LMIC.

Methods and analysis: A systematic search for studies will be conducted in African Index Medicus, Africa Portal Digital Library, CINAHL, Embase, Index Medicus for the South-East Asia Region, IndMed, LILACS, Medecins Sans Frontieres, Medline, Minority Health and Health Equity Archive, ProQuest, PsychInfo, SciELO, and Social Policy and Practice. Studies will be in English, Spanish, and Portuguese, published between 2007 and 2017, addressing IPV against women from LMIC, whose data quantitatively report on the impacts/outcomes for survivors and/or workers and/or public health systems pre- and post-intervention. Two trilingual reviewers will independently screen for study eligibility and data extraction, and a librarian will cross check for compliance. Risk of bias and quality assessment of studies will be measured according to: (1) the Cochrane Collaboration's tool for assessing risk of bias for randomised controlled trials; and (2) the methodological index for non-randomised studies (MINORS). Data will be analysed and summarised using meta-analysis and narrative description of the evidence across studies. This systematic review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.

Ethics and dissemination: This systematic review will be based on published studies, thus not requiring ethical approval. Findings will be presented in conferences and published in a peer-reviewed journal.

Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42017069261

Strengths and limitations of this study

- The comprehensive search strategy of this systematic review will allow identification of a range of interventions from different LMIC published in peer-reviewed journals in English, Spanish and Portuguese.
- This protocol is co-authored by researchers from LMIC, who are native-speakers of the languages included in this systematic review. This can strengthen the review process given linguistic and cultural aspects of the diverse studies will be recognised.
- The review intends to promote voices from LMIC, who otherwise may go unheard, given relative financial barriers of LMIC research institutions and the publication bias to English.
- It is expected that there will be some variability related to methodological diversity and outcomes of the reviewed studies, due to the broad scope of PHC interventions addressing IPV, making it challenging to compare outcomes across different scenarios.

INTRODUCTION

Intimate partner violence (IPV) is the most prevalent type of violence against women. The World Health Organization (WHO) estimates that one in three women experience physical or sexual IPV during their lifetime¹. IPV against women is defined by the WHO as any behaviour within an intimate relationship that causes physical damage, psychological or sexual abuse to a woman in the

relationship, including physical assault, psychological abuse, forced intercourse, and other forms of sexual coercion and of controlling behaviours².

The consequences of IPV for women's health have been extensively described, demonstrating that abused women have poorer health compared to women who have never been abused^{3 4}. There are a wide range of impacts, including: a) physical health, such as injuries, traumas, cardiovascular effects⁵; b) mental health, including depression, anxiety, post-traumatic stress disorder (PTSD), alcohol and drug abuse and suicide⁶; c) sexual and reproductive health, including sexually transmitted diseases (STD), miscarriage, reduced contraception and sexual autonomy⁷. The impacts are not only for women, but also for their children, including increased risk for low birth weight, preterm delivery, and neonatal death⁷.

IPV against women is a common problem all over the world, but multicountry studies reveal higher prevalence and the worst consequences for women from low-and-middle-income countries (LMIC)³. The World Bank classifies all countries by income, based on the gross national income (GNI) per capita⁸. It consists of four categories: 1) low-income (with a GNI per capita \leq US\$1,025 in 2015); 2) lower middle-income (GNI per capita between US\$1,026 and US\$4,035); 3) upper middle-income (GNI per capita between US\$4,036 and US\$12,475); and 4) high-income countries (GNI per capita US\$12,476). This classification is based on the gross national income (GNI) per capita of nations as of March, 2017. For the purpose of this review, we will include all categories, except the high-income, which is outside the scope of LMIC.

IPV has been recognized as a public health issue and included in the agendas of public health systems worldwide. The WHO Sustainable Development Goal number 5 aims to achieve gender equality and empower all women and girls. It includes two subitems targeting violence specifically: 5.1 'End all forms of discrimination against all women and girls everywhere'; and 5.2 'Eliminate all forms of violence against all women and girls in the public and private spheres, including trafficking and sexual and other types of exploitation'⁹. The World Health Assembly in 2016 recommended actions¹⁰ under four strategic directions: 1) strengthening health system leadership and governance; 2) strengthening health service delivery and health workers'/providers' capacity to respond to violence, in particular against women and against children; 3) strengthen programming to prevent interpersonal violence, in particular against women and girls and against children; and 4) improve information and evidence. Each country responds differently to the problem in the health arena, and exchanging experiences can be a significant opportunity to foster local debate and action¹¹. This systematic review focuses on experiences conducted within public health systems, and more specifically, in primary health care setting.

Primary health care (PHC) can be considered both a philosophy and a system response to reducing health inequities and ameliorating the effects of disadvantage¹². PHC is the first level of contact individuals, families and communities have with the healthcare system. Ever since its definition was drawn up in 1978 by the WHO in the Alma-Ata declaration,¹³ there has been much debate about the scope of PHC. In this study, we adopt a more recent definition of PHC, consisting of 'a socially appropriate, universally accessible, scientifically sound first level care provided by health services and systems with a suitably trained workforce comprised of multidisciplinary teams supported by integrated referral systems in a way that: gives priority to those most in need and addresses health inequalities; maximises community and individual self-reliance, participation and control; and involves collaboration and partnership with other sectors to promote public health'¹⁴.

Globally, numerous LMIC are developing innovative interventions addressing IPV against women with a focus on PHC¹⁵. However, some of these interventions often go unnoticed by mainstream researchers from high-income countries. This can be related to different factors, such as: 1) the high costs for the development of complex interventions considered the gold standard of research (e.g.: randomised controlled trials); 2) high publication costs in prestigious academic journals, accompanied by high standards which are difficult to achieve by LMIC researchers given scarce resources, and; 3) linguistic barriers, as writing papers in English—the dominant language for publication in prestigious journals of high income countries—can be very expensive for non-English speaking researchers. However, such interventions developed in LMIC are not necessarily low quality studies. Indeed, they

1
2
3 can be scalable and generalisable, affording insights for public health systems in other contexts,
4 including both high-income countries and LMIC.

5 While previous reviews have been published in this area, they are either not systematic reviews^{16 17}, or
6 if systematic, did not focus solely on LMIC¹⁸, or if focusing on LMIC, did not make reference to
7 PHC¹⁹. Moreover, none of the extant systematic reviews include studies in Spanish or Portuguese, nor
8 searched regional databases for literature. Thus, this will be the first systematic review addressing IPV
9 interventions in PHC from LMIC to include studies in English, Spanish, and Portuguese, retrieved
10 from, amongst others, regional databases.

11 **REVIEW QUESTIONS**

- 12
13 1) Do primary health care interventions within public health systems improve the health, safety and
14 wellbeing of women survivors of IPV in LMIC?
15 2) What are the main impacts/outcomes of these interventions for PHC workers and their
16 sustainability for public health systems?
17

18 **OBJECTIVES**

19 To conduct a systematic review of quantitative studies focusing on pre-and-post primary health care
20 interventions conducted in LMIC, whose aim is the prevention/reduction of IPV and the improvement
21 of survivors' health, safety and wellbeing.
22

23 **METHODS**

24 This systematic review will be conducted and reported according to the guidelines of the Preferred
25 Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P)^{20 21}, which
26 includes the use of the PRISMA-P checklist (see appendix 1), following methodological approaches
27 published in previous studies²². The review will be published according to the recommended items for
28 systematic reviews based on the PRISMA statement²². This review will also be informed by the
29 guidelines of the Cochrane Handbook²³ for systematic reviews of interventions to reinforce rigour
30 along the process.
31
32
33

34 **Study registration**

35 This systematic review is registered in the PROSPERO International Prospective Register of
36 Systematic Reviews with number CRD42017069261.
37 (http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017069261)
38
39
40
41

42 **Types of studies**

43 In this review we will include studies with quantitative pre-and-post evaluation concerning PHC
44 interventions of IPV against women from LMIC developed within their respective public health
45 systems. For the purposes of this review, we will consider interventions as proposed by
46 Blankenship²⁴, consisting on actions generally taken by outsiders (often read experts), but including
47 individuals and collectives who take actions on their own behalf, purposefully to address a particular
48 risk or disease. This can include individual interventions (focused on individuals' knowledge,
49 attitudes and behaviors) or structural interventions (aiming to change structural factors, such as
50 economic, politico-legal, physical, and social environment). The interventions can include the
51 following experimental approaches: randomised controlled trial, non-randomised controlled trial,
52 quasi-experimental, and pre-post design. We will not include observational studies, qualitative
53 methodologies, or prevalence studies.
54
55
56
57
58
59
60

1
2
3 We license the inclusion of a broad type of interventions by acknowledging the relatively poor
4 funding allotted to research in LMIC. While cognisant that RCTs, for example, are the gold standard
5 in research, and further, that the Cochrane Collaboration largely recommends methodologically-
6 randomised studies to be the focus of review, we argue that filtering solely for such studies would
7 miss many interventions employed in LMIC - the economic capital in LMIC simply does not allow
8 for it. Given our aim is to “hear voices for the LMIC,” and encouraged by the Cochrane’s recognition
9 that non-RCTs may be more appropriate at times²³, our approach is expansive.
10

11 **Types of participants and settings**

12 We recognise that the definition of PHC can be considered both a utopia and an aim. For the purpose
13 of this review, we will include any healthcare facility considered as a Primary Healthcare Centre, but
14 restricted to public health services from LMIC. The WHO²⁵ defines Primary Healthcare Centres as
15 centres providing services which are usually the first point of contact with a health professional. They
16 include services provided by general practitioners, dentists, community nurses, pharmacists and
17 midwives, among others. It can include, for example, General Practice Clinics, Community Based
18 Units, Basic Health Units, Family Health Strategy, Primary Care Home Visits, Day Care Centres,
19 Multicentre Health Clinics and One Stop Crisis Center. This review will not include studies of
20 interventions conducted outside of PHC centres and from the public health systems, such as media
21 campaigns, interventions in schools or in hospitals, which are considered tertiary level of care.
22
23

24 Interventions in PHC for IPV usually focus on workers’ strategies to improve survivors’ health. This
25 can include healthcare professionals, paraprofessionals, managers and other workers, like
26 receptionists, for example. By ‘survivors’¹⁰ we mean any women older than 16 years-old affected by
27 IPV and part of the population of an intervention of PHC centres from low- and middle-income
28 countries.
29
30

31 **Intervention(s), exposure**

32 The types of interventions will include: studies about implementation of public policies to
33 reduce/prevent IPV targeting PHC centres; education/training of PHC workers to manage IPV
34 survivors; screening or case-finding IPV in PHC settings; strategies for organizational changes in
35 PHC centres aiming to improve survivors' health, safety or wellbeing; therapeutic interventions for
36 IPV focused in PHC centres.
37
38
39
40

41 **Comparator(s)/control**

42 Studies with all types of control conditions will also be included in this review, including no treatment
43 group, treatment as usual, or comparison. We will not limit our review only to studies that compare
44 active interventions with a control condition.
45
46
47

48 **Types of outcomes measures**

49 **Primary outcomes**

50 Primary outcomes will include the impacts/outcomes of the intervention for:

- 51 a) IPV, measured by validated instruments (such as the Composite Abuse Scale²⁶, Index of Spouse
52 Abuse²⁷, etc.) or self-reported IPV (even if adopting unvalidated scale).
- 53 b) women’s perceived and diagnosed physical, psychological or sexual health and wellbeing, using
54 validated instruments for each domain (such as General Health Questionnaire²⁸, Center for
55 Epidemiologic Studies Depression Scale - CESD²⁹ - Post Traumatic Stress Disorder Checklist³⁰, the
56
57
58
59

1
2
3 Short-Form Health Survey - SF-36³¹, etc.).

4 c) women's safety, adopting validated or unvalidated measures (such as safety plans, danger
5 assessment³², etc.).

6 d) PHC workers, including (i.) identification of abuse by workers; (ii.) information-giving or safety
7 planning and (iii) referral to other services within the public health system (such as hospitals,
8 emergency settings, etc.) (iv.) referral to other services beyond the public health (such as family
9 violence support agencies, police, justice, housing, etc.);

10
11 Other outcomes (secondary outcomes)

12 Secondary outcomes will include the impacts/outcomes of the intervention for:

13 a) children, considering intimate partner abuse also affects children, assessments through validated
14 instruments regarding children's health and wellbeing will also be reviewed (such as Child Health
15 Questionnaire – CHQ³³, etc.).

16 b) public health systems, considering: (i.) policies about system and worker responses, (ii.) training
17 programs in place, (iii.) routine data collection, (iv.) guidelines for workers, (v.) funding allocation
18 and cost/benefit measures, and (vi.) sustainability, considering for this analysis only follow-up
19 evaluations conducted no less than 12 months after the conclusion of the intervention.
20
21

22 **Search strategy**

23 A systematic search will be conducted for literature published between 1 January 2007 and 31 July
24 2017. We choose this time range given the first multi-country study addressing our question in the
25 context of LMIC was published in 2006³.
26

27 The following databases will be searched: African Index Medicus, Africa Portal Digital Library,
28 Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Index Medicus for the
29 South-East Asia Region, IndMed, Latin American and Caribbean Health Science Information
30 Database (LILACS), Medecins Sans Frontieres, Medline, Minority Health and Health Equity Archive,
31 ProQuest, PsychInfo, Scientific Electronic Library Online (SciELO), Social Policy and Practice.
32

33 This review considers studies published in English, Spanish, and Portuguese, given these are the
34 official languages of 69 of the 145 LMIC (World Bank). Earlier systematic reviews¹⁹ concerning
35 interventions to IPV in LMIC did not consider articles in languages other than English. This review
36 team consists of authors native in the three languages included, minimizing bias related to language.
37 Accordingly, keywords and MeSH will be translated from English by author 1 and reviewed by
38 authors 3 (to Portuguese) and 4 (to Spanish).

39 Authors 1 and 2 independently considered keywords and MeSH headings. Any discrepancies were
40 subjected to justification. The general search strategy is shown in appendix 2, and will be adapted and
41 modified appropriately according to each database.
42

43 **Data collection and analysis**

44 **Eligibility criteria of the studies:**

45 The inclusion criteria will be:
46

- 47 1. Studies from the eligible bibliographic databases with selected (combination of) terms and
48 keywords (appendix 2), published in English, Spanish or Portuguese, between 2007 and 2017.
- 49 2. Interventions addressed to IPV conducted in PHC centres within the public health systems
50 from LMIC.
- 51 3. Quantitative pre-and-post studies assessing the impacts/outcomes for survivors and/or
52 workers and/or public health systems.
- 53 4. Primary data collection or existing data set analysis.
54
55
56
57
58
59
60

1
2
3 The exclusion criteria will be:

- 4 1. Studies published in languages other than English, Spanish or Portuguese.
- 5 2. Interventions from non-LMIC or not-conducted in PHC centres or conducted only in the
6 private health system.
- 7 3. Studies that did not quantitatively assess pre-and-post interventions or that did not describe
8 the impacts/outcomes for survivors, workers or public health systems.
- 9 4. Studies not related to interventions for IPV against women (for example, studies that focus
10 only in children abuse or studies that focus only in risk factors for IPV or association factors
11 between clinical manifestations and IPV).
- 12 5. Grey literature, including any study protocols, theses, case reports, letters, opinions,
13 editorials, weekly reports, policy documents, congress abstracts, theoretical papers,
14 observational studies, qualitative studies or reviews.
- 15 6. Studies published in 2006 or earlier or with the full text not available in the eligible databases.
- 16 7. Duplicate studies that have used the same study population or data. In this case, it will be used
17 only the most recent or relevant publication, for researches published in more than one
18 journal.
19
20
21

22 **Data management of the studies**

23
24 COVIDENCE (www.covidence.org) will be employed to manage retrieved studies and to conduct the
25 systematic review process. The bibliographic software platform Endnote (online version
26 www.myendnoteweb.com) will also be used to manage and store relevant studies for this review.
27 These softwares will remove duplicates thereby cleaning the sample. A checklist will be developed
28 based on the eligibility criteria of this review. The flow diagram showing the main steps of this
29 systematic review is available on Appendix 3, following the PRISMA statement^{20 21}.

31 **Data selection of the studies**

32
33 The first step consists of the screening of potential studies. This will be done independently and
34 blinded by two investigators fluent in the three languages included in this review (Authors 1 and 3).
35 They will analyse titles and abstracts, considering also full texts of all non-duplicate papers from the
36 electronic search, assessing their eligibility. This process was previously described³⁴ for rigorous
37 systematic reviews, considering it can be necessary to read and evaluate the studies in this initial step.
38 Additionally, some papers may not describe precisely their abstracts, so this manual and detailed
39 search is proposed to maximise the inclusion of studies. Following Ayala-Quintanilla and
40 colleagues³⁴, if there is uncertainty about the inclusion of a certain study in this step, that study will be
41 temporarily included and will proceed to the next step for more evaluation. Considering all the
42 selected databases provide an English version of their titles and abstracts, a librarian (Author 2) will
43 cross-check this first step, comparing the independent results obtained from each investigator and
44 ensuring that all steps were conducted in compliance with the protocol. If there is any uncertainty
45 between the resultant studies, the librarian will seek for an opinion from one of the advisors (Authors
46 5 and 6) that compose this review team.
47

48
49 The second step consists of examining the full version of all selected studies from the first step,
50 concerning the selection criteria. Two investigators will analyse independently all the articles for each
51 language. The librarian will double check it this process.

52
53 The final list of selected studies will be reviewed independently. For each exclusion, justification will
54 be documented. The results will be compared by the librarian, and any disagreements will be
55 discussed and if necessary, consultation with a third author will occur to reach the consensus.

56 **Appraisal/assessment of the risk of bias of the included studies**

1
2
3 It is expected that eligible studies will vary according to their methodological approach. There is a
4 vast range of tools to assess the quality and bias of studies. Nevertheless, evaluating such biases and
5 qualities is a challenging task and there is no consensus to conduct it.

6 Grading of Recommendations, Assessment, Development and Evaluation (GRADE)³⁵ and the
7 EQUATOR (Enhancing the Quality and Transparency of health Research) Network³⁶ provide support
8 with guidelines and tools to evaluate the studies, rating up according to the level of evidence.
9

10 In this review, to minimize the risk of bias and evaluate the quality of evidence of each article
11 included, we will adopt: 1) the Cochrane Collaboration's tool for assessing risk of bias for randomised
12 controlled trials³⁷; 2) the Methodological index for non-randomised studies (MINORS)³⁸ to assess
13 non-randomised interventional studies. This process will be independently performed by different
14 authors (two authors for articles written in English, two for studies written in Portuguese, and two for
15 articles in Spanish) and any disagreement will be discussed and resolved by a third author, if needed.
16
17

18 **Data extraction**

19 For this third step, three investigators (Authors 1, 3 and 4) will independently and blindly extract all
20 data items (see appendix 4) of each included study with a standardised data collection form. The first
21 author will extract data from studies in English and Portuguese. The third author will extract data
22 from studies in Portuguese and Spanish, while the fourth author will collect from Spanish and
23 English. All extracted data will be converted into English by authors for articles in Spanish or
24 Portuguese, to allow the analysis by all authors in a common language for all. To guarantee that no
25 errors will be made, the librarian (Author 2) will randomly cross-check these data. Any disagreements
26 will be resolved by consensus between the two authors collecting each language and a third author
27 (Author 5 or 6) can be arbitrator if consensus is not reached, following other systematic review
28 protocols³⁴.
29

30 **Data items**

31 The descriptive items that will be collected are (see appendix 4): (1) general information and
32 characteristics of the study, including the country/place, type of service where it was conducted, target
33 participants and their main sociodemographic characteristics; (2) methodological characteristics,
34 including the type of method and how data/information were collected, components that were
35 analysed/; (3) impacts/outcomes for survivors, including IPV rates, women's health, safety and
36 wellbeing and also impacts for their children; (4) impacts/outcomes for PHC workers, including types
37 of workers, their roles and concerning measures; (5) impacts/outcomes for the public health systems,
38 including measures of articulation with other levels of care (for example, hospitals, emergency units,
39 intensive care units, etc) and other sectors beyond the public health (for example, housing, financing,
40 police, justice, social services, etc), and also evaluation of costs and sustainability of the intervention.
41 For items 3, 4 and 5, we will also collect information about barriers and facilitators for each of the
42 three components (survivors, workers and systems), if available.
43
44
45
46
47

48 **Data synthesis and analysis**

49 Data extracted will be analysed and summarised aiming to answer the research questions. Data will be
50 summarised according to the outcomes: 1) for survivors, including their health, safety and wellbeing
51 as well as impacts on IPV rates; 2) for PHC workers considering their role to improve survivors'
52 health care, and 3) for public health systems, including evaluation of costs and sustainability.
53

54 When appropriate, a meta-analysis can be conducted, if a sufficient number of trials are identified
55 with sufficient homogeneity. The meta-analysis will be conducted with aggregate data, rather than at
56 the individual participant level. Continuous and categorical variables will be summarised according to
57
58
59

1
2
3 the presentation of data of each study. Dichotomous outcome data (yes/no experience of IPV) will be
4 described as risk ratios with their 95% confidence intervals. It will also be indicated if those findings
5 were adjusted for confounders. It is anticipated that there will be some variability of reporting
6 impacts/outcomes of interventions across studies. In this case, a narrative description of the available
7 evidence will be conducted instead. This will consider which results are significant and their
8 association with the outcomes, based on data availability across studies.

9 This review will present the results reported in the original studies which implies that we will not
10 reanalyse or recalculate the data if a study does not report appropriate results. However, as indicated
11 previously, we will calculate data, where possible, using the original information from the study such
12 as for IPV or women's health, safety and wellbeing. In addition, quantitative data from figures can be
13 utilised if there is sufficient information reported/explained in the study. Additional data analysis can
14 be made in order to assess the comparisons between studies, if possible.

15
16 For duplicate studies that have used the same study population or data, the most recent or relevant
17 publication will be utilised for studies published in more than one journal, if possible the data will be
18 linked together.

19 In summary, data analysis will be performed according to the data availability of eligible studies, and
20 statistical expertise will be consulted as needed. The software STATA (version 15) will be utilised for
21 all the quantitative analyses.
22

23 24 **Cochrane's recommendations for reviews in public health**

25
26 This review will follow some of the Cochrane guidelines for reviews conducted in public health and
27 health promotion scenarios. One of the key points is sustainability, referred by The Cochrane
28 Collaboration Group²³ as an important aspect to be included in systematic reviews in public health
29 contexts, because it is likely to increase the concern of policymakers, practitioners and funders. When
30 sustainability was measured in eligible studies we will look for additional explanations about which
31 outcomes were measured over what period. However, if it was not measured, but authors explore the
32 potential for sustainability it will also be summarised.
33

34 Another Cochrane²³ recommendation for systematic reviews in public health is the consideration of
35 applicability and transferability. Applicability refers to how the findings of a given study or review
36 can be translated into specific population or settings. Transferability is also referred as the potential
37 for this translation occurs. If the reviewed studies mention these aspects, they will also be included in
38 the analysis.
39

40 **Economic evidences**

41
42 Cochrane²³ recommends the review of economic evidences, because it provides additional
43 information for decision makers, considering not only if a strategy or intervention works, but also
44 whether its adoption will improve the use of resources. The economic issues are not the main
45 objective of this review, therefore, it will not be an inclusion or exclusion criteria, but will compose
46 an additional source of information when mentioned in the studies. We believe this information will
47 be particularly important for LMIC and summary will be presented when described in eligible studies.
48

49 **PRESENTING AND REPORTING THE RESULTS**

50
51 The process of selection of eligible studies for the systematic review will follow the flow diagram
52 according to guidelines of the PRISMA-P (appendix 1). The main steps of the review will include: the
53 identification of studies, screening, evaluation according to inclusion/exclusion criteria and analysis of
54 eligible studies. Results will be presented according to the outcomes: for survivors; for PHC workers;
55 and for public health systems. Data will be summarized in tables depending on data from each study,
56 but presenting first author's name, country, year of publication, study design, aims and main
57
58
59

1
2
3 outcomes.

4 **POTENTIAL AMENDMENTS**

5
6 This protocol is designed to guide with rigour all the steps of this systematic review. Amendments are
7 not expected, but if necessary, just in case of any unexpected event, they will be reported in a detailed
8 and consistent way, followed by appropriate justification. The same will be applied to any differences
9 between the protocol and the review. In case of differences, they will be fully described in a specific
10 section of the final review, providing rationale for them.
11

12 **CONCLUSION AND IMPLICATIONS**

13
14 Intimate partner violence is one of the main public health problems for women's health, safety and
15 wellbeing. It requires effective and sustainable actions to reduce harm and life-threatening, targeting
16 comprehensive interventions, particularly in primary health care settings in low-and-middle income
17 contexts. This challenge is more severe in developing countries and exchanging effective
18 interventions can be a coordinated way to foster debate and action. This review will systematise the
19 knowledge previously produced, identifying research gaps and opportunities on interventions
20 conducted in LMIC.
21

22
23 IPV is a potentially preventable issue, but its complexity requires the articulation of different sectors
24 (including health systems, education, justice, among others), in different levels (highlighting the key
25 potential role of the primary care level, but connecting to other levels), with collaboration of different
26 actors (such as health professionals, managers, police, etc.) and with different targets (survivors,
27 perpetrators, families, communities, etc.).
28

29
30 Facing this complex scenario, it is significant to recognize the limitations of this review, such as the
31 types of studies included, that do not include all possible methodological approaches conducted in
32 LMIC. Another limitation is the possible diversity of interventions, that can be challenging to be
33 compared and systematised. It could be possible that other relevant studies will be excluded, since this
34 review includes only studies published in English, Portuguese and Spanish. It is important to mention
35 that the findings of this systematic review will be cautiously interpreted and the conclusions will be
36 presented with parsimony, considering such limitations. This review will only focus in a 'tip of the
37 iceberg', but it can raise questions for future studies with focus, for example, in other levels of care or
38 in other sectors rather than the public health or even including other methodological approaches, such
39 as qualitative studies, which have been extensively reported in LMIC.
40

41 **ETHICS AND DISSEMINATION**

42 **Ethical issues**

43
44 This systematic review is based on studies previously published and does not include collection of
45 new primary data. Consequently, it is not necessary to obtain ethical evaluation.
46

47 **Publication Plan**

48
49 This review will be publicized in conferences (preliminary results) and the final article will be
50 published in a peer-reviewed journal. We intend to publish both the protocol and the systematic
51 review in open access journals, aiming to be accessible to investigators currently engaged in
52 interventions in low-and-middle-income countries. This review affords a voice to researchers in the
53 field of IPV who would otherwise go unheard, and provide greater insights into the range of possible
54 interventions for nations facing comparable issues. It is expected that the final publication can support
55 public systems and policies worldwide.
56
57
58
59
60

Author's contributions

MS conceived the review. SH, BQ and AT assisted on the design of the study protocol. MS and SH drafted the protocol paper and all authors edited the subsequent versions. AT critically revised the methodology. All authors have reviewed and approved the final version of the text.

Funding: This work was supported by the Brazilian CAPES Foundation which funded a scholarship for postdoctoral studies of the first author [Process number 88881.119273/2016-01]. The funder had no role on this protocol development.

Competing interests: none

REFERENCES

1. World Health Organization (WHO). Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence. Geneva: World Health Organization Department of Reproductive Health and Research, London School of Hygiene and Tropical Medicine, South African Medical Research Council., 2013.
2. Krug EG, Mercy JA, Dahlberg LL, et al. The world report on violence and health. *Lancet* 2002;360(9339):1083-8. doi: 10.1016/S0140-6736(02)11133-0
3. Garcia-Moreno C, Jansen HA, Ellsberg M, et al. Prevalence of intimate partner violence: findings from the WHO multi-country study on women's health and domestic violence. *Lancet* 2006;368(9543):1260-9. doi: 10.1016/S0140-6736(06)69523-8
4. Campbell JC. Health consequences of intimate partner violence. *Lancet* 2002;359(9314):1331-6. doi: 10.1016/S0140-6736(02)08336-8
5. Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate partner violence for men and women. *Am J Prev Med* 2002;23(4):260-8.
6. Dutton MA, Green BL, Kaltman SI, et al. Intimate partner violence, PTSD, and adverse health outcomes. *J Interpers Violence* 2006;21(7):955-68. doi: 10.1177/0886260506289178
7. Sarkar NN. The impact of intimate partner violence on women's reproductive health and pregnancy outcome. *J Obstet Gynaecol* 2008;28(3):266-71. doi: 10.1080/01443610802042415
8. World Bank Country and Lending Groups. Washington: World Bank, 2017.
9. United Nations. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015:31.
10. Organization WH. Global plan of action to strengthen the role of the health system within a national multisectoral responseto address interpersonal violence, in particular against women and girls, and against children. In: research Dfrha, ed. Geneva: WHO, 2016:76.
11. Signorelli MC, Taft A, Pereira PP. Intimate partner violence against women and healthcare in Australia: charting the scene. *Cien Saude Colet* 2012;17(4):1037-48.
12. Keleher H. Why primary health care offers a more comprehensive approach to tackling health inequities than primary care. *Australian Journal of Primary Health* 2001;7(2):5.
13. Care ICOPH. Declaration of Alma-Ata. *WHO Chron* 1978;32(11):428-30.
14. Australian Primary Health Care Research Institute (APHCRI). What is primary health care? In: (APHCRI). Canberra: Australian Primary Health Care Research Institute (APHCRI), 2009.
15. Abramsky T, Devries K, Kiss L, et al. Findings from the SASA! Study: a cluster randomized controlled trial to assess the impact of a community mobilization intervention to prevent violence against women and reduce HIV risk in Kampala, Uganda. *BMC Med* 2014;12(1):122. doi: 10.1186/s12916-014-0122-5
16. Colombini M, Mayhew S, Watts C. Health-sector responses to intimate partner violence in low- and middle-income settings: a review of current models, challenges and opportunities. *Bull*

- 1
2
3 *World Health Organ* 2008;86(8):635-42.
- 4 17. Bacchus LJ, Colombini M, Contreras Urbina M, et al. Exploring opportunities for coordinated
5 responses to intimate partner violence and child maltreatment in low and middle income
6 countries: a scoping review. *Psychol Health Med* 2017;22(sup1):135-65. doi:
7 10.1080/13548506.2016.1274410 [published Online First: 2017/02/02]
- 8 18. Bair-Merritt MH, Lewis-O'Connor A, Goel S, et al. Primary care-based interventions for intimate
9 partner violence: a systematic review. *Am J Prev Med* 2014;46(2):188-94. doi:
10 10.1016/j.amepre.2013.10.001
- 11 19. Bourey C, Williams W, Bernstein EE, et al. Systematic review of structural interventions for
12 intimate partner violence in low- and middle-income countries: organizing evidence for
13 prevention. *BMC Public Health* 2015;15:1165. doi: 10.1186/s12889-015-2460-4 [published
14 Online First: 2015/11/23]
- 15 20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-
16 analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-
17 4-1 [published Online First: 2015/01/01]
- 18 21. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-
19 analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647.
20 [published Online First: 2015/01/02]
- 21 22. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-
22 analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62(10):1006-12. doi:
23 10.1016/j.jclinepi.2009.06.005 [published Online First: 2009/07/23]
- 24 23. Higgins J, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. West
25 Sussex: The Cochrane Collaboration and John Wiley & Sons, 2008.
- 26 24. Blankenship KM, Friedman SR, Dworkin S, et al. Structural interventions: concepts, challenges
27 and opportunities for research. *J Urban Health* 2006;83(1):59-72. doi: 10.1007/s11524-005-
28 9007-4
- 29 25. WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean
30 Care Is Safer Care. Appendix 1 Definitions of health-care settings and other related terms.
31 Geneva: World Health Organization, 2009.
- 32 26. Hegarty K, Fracgp, Bush R, et al. The composite abuse scale: further development and assessment
33 of reliability and validity of a multidimensional partner abuse measure in clinical settings.
34 *Violence Vict* 2005;20(5):529-47.
- 35 27. Campbell DW, Campbell J, King C, et al. The reliability and factor structure of the index of
36 spouse abuse with African-American women. *Violence Vict* 1994;9(3):259-74.
- 37 28. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. *Psychol Med*
38 1979;9(1):139-45.
- 39 29. Eaton W, Smith C, Ybarra M, et al. Center for Epidemiologic Studies Depression Scale: review
40 and revision (CESD and CESD-R). In: Maruish M, ed. *The Use of Psychological Testing for*
41 *Treatment Planning and Outcomes Assessment*. 3 ed. Mahwah, NJ: Lawrence Erlbaum
42 Associates, Inc, 2004.
- 43 30. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary
44 care. *Behav Res Ther* 2005;43(5):585-94. doi: 10.1016/j.brat.2004.04.005
- 45 31. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual
46 framework and item selection. *Med Care* 1992;30(6):473-83.
- 47 32. Campbell JC. Nursing assessment for risk of homicide with battered women. *ANS Adv Nurs Sci*
48 1986;8(4):36-51.
- 49 33. Landgraf J, Abetz L, Ware J. *The Child Health Questionnaire (CHQ) user's manual*. 1st ed. ed.
50 Boston: TheHealth Institute, New England Medical Centre, 1996.
- 51 34. Ayala Quintanilla BP, Taft A, McDonald S, et al. Social determinants and maternal exposure to
52 intimate partner violence of obstetric patients with severe maternal morbidity in the intensive
53 care unit: a systematic review protocol. *BMJ Open* 2016;6(11):e013270. doi:
54 10.1136/bmjopen-2016-013270 [published Online First: 2016/11/28]
- 55 35. Schünemann HJ, Schünemann AH, Oxman AD, et al. Grading quality of evidence and strength of
56 recommendations for diagnostic tests and strategies. *BMJ* 2008;336(7653):1106-10. doi:
57 10.1136/bmj.39500.677199.AE

- 1
2
3 36. Pandis N, Fedorowicz Z. The international EQUATOR network: enhancing the quality and
4 transparency of health care research. *J Appl Oral Sci* 2011;19(5)
5 37. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk
6 of bias in randomised trials. *BMJ* 2011;343:d5928. [published Online First: 2011/10/18]
7 38. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors):
8 development and validation of a new instrument. *ANZ J Surg* 2003;73(9):712-6.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1 - PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page number
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not an update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	PROSPERO CRD42017069261
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	11
Sponsor	5b	Provide name for the review funder and/or sponsor	11
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	11
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	3,4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4, 5, 6, 7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Detailed on Appendix 2
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	8 and Appendix 4
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5, 6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	7, 8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8,9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	8, 9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Not applicable
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8, 9
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Not applicable
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix 2 - General Search Strategy

1. ('primary health care*' or 'primary care*' or 'primary health*' or 'primary health care interven*' or 'health* manag*' or 'care manag*' or 'primary health interven*' or 'prevent* program*' or 'prevent* interven*' or 'early interven*' or 'primary health*' or 'strateg*' or 'health promot*' or 'comprehensive health*' or 'community health*' or 'famil* health*' or 'public health*' or 'health* system*' or 'health* worker*' or 'health* profession*' or 'health* polic*' or 'antenatal car*' or 'antenatal clinic*' or 'basic health*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

2. Primary Health Care/ or Public Health/ or Health Policy/ or Health Promotion/ or Health Personnel/ or Developing Countries/

3. 1 {or/and} 2

4. ('partner violen*' or 'partner abus*' or 'spouse violen*' or 'spouse abus*' or 'partner harm*' or 'violen* against wom*' or 'battered women' or 'dating violen*' or 'dating abus*' or 'gender based violen*' or 'gender based abus*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

5. Intimate Partner Violence/ or Battered Women/

6. 4 {or/and} 5

7. ('low* middle* incom* countr*' OR 'low* incom* countr*' OR 'middle* incom* countr*' OR 'underdevelop* countr*' OR 'developing countr*' OR 'third* world countr*' OR 'low* middle* income* nation*' OR 'third*world* nation*' OR 'underdevelop* nation*' OR 'less* developed nation*' OR 'low* income nation*' OR 'developing nation*' OR 'least* developed countr*' OR 'emerg* countr*' OR 'less-developed countr*' OR 'developing world*' OR 'undeveloped world*' OR 'emerg* world' OR 'Latin* America*' OR 'Central* America*' OR 'Caribbean' OR 'South* America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle* East*' OR 'Latin* America*' OR 'Central America*' OR 'South America*' OR 'Africa*' OR 'Asia*' OR 'Pacific*' OR 'Middle East*' OR 'Afghanistan' OR 'Albania' OR 'Algeria' OR 'American Samoa' OR 'Angola' OR 'Argentina' OR 'Armenia' OR 'Azerbaijan' OR 'Bangladesh' OR 'Belarus' OR 'Belize' OR 'Benin' OR 'Bhutan' OR 'Bolivia' OR 'Bosnia*Herzegovina' OR 'Botswana' OR 'Brazil' OR 'Bulgaria' OR 'Burkina Faso' OR 'Burundi' OR 'Cabo Verde' OR 'Cambodia' OR 'Cameroon' OR 'Central African Republic' OR 'Chad' OR 'China' OR 'Colombia' OR 'Comoros' OR 'Congo, Dem* Rep*' OR 'Congo, Rep*' OR 'Costa Rica' OR 'Cote d'Ivoire' OR 'Cuba' OR 'Djibouti' OR 'Dominica' OR 'Dominican Republic' OR 'Ecuador' OR 'Egypt' OR 'El Salvador' OR 'Equatorial Guinea' OR 'Eritrea' OR 'Ethiopia' OR 'Fiji' OR 'Gabon' OR 'Gambia' OR 'Georgia' OR 'Ghana' OR 'Grenada' OR 'Guatemala' OR 'Guinea' OR 'Guinea-Bissau' OR 'Guyana' OR 'Haiti' OR 'Honduras' OR 'India' OR 'Indonesia' OR 'Iran' OR 'Iraq' OR 'Jamaica' OR 'Jordan' OR 'Kazakhstan' OR 'Kenya' OR 'Kiribati' OR 'Korea, Dem* People's Rep*' OR 'North Korea' OR 'Kosovo' OR 'Kyrgyz' OR 'Lao' OR 'Lebanon' OR 'Lesotho' OR 'Liberia' OR 'Libya' OR 'Macedonia' OR 'Madagascar' OR 'Malawi' OR 'Malaysia' OR 'Maldives' OR 'Mali' OR 'Marshall Islands' OR 'Mauritania' OR 'Mauritius' OR Mexico' OR 'Micronesia' OR 'Moldova' OR 'Mongolia' OR 'Montenegro' OR 'Morocco' OR 'Mozambique' OR 'Myanmar' OR 'Namibia' OR 'Nepal' OR 'Nicaragua' OR 'Niger' OR 'Nigeria' OR 'Pakistan' OR 'Palau' OR 'Palestine' OR 'Panama' OR 'Papua New Guinea' OR 'Paraguay' OR 'Peru' OR 'Philippines' OR 'Romania' OR 'Russian Federation' OR 'Russia' OR 'Rwanda' OR 'Samoa' OR 'Sao Tome and Principe' OR 'Senegal' OR 'Serbia' OR 'Sierra Leone' OR 'Solomon Islands' OR 'Somalia' OR 'South Africa' OR 'South Sudan' OR 'Sri Lanka' OR 'St. Lucia' OR 'St. Vincent and the Grenadines' OR 'Sudan' OR 'Suriname' OR 'Swaziland' OR 'Syrian Arab Republic' OR 'Syria' OR 'Tajikistan' OR 'Tanzania' OR 'Thailand' OR 'Timor-Leste' OR 'East Timor' OR 'Togo' OR 'Tonga' OR 'Tunisia' OR 'Turkey' OR 'Turkmenistan' OR 'Tuvalu' OR 'Uganda' OR 'Ukraine' OR 'Uzbekistan' OR 'Vanuatu' OR 'Venezuela' OR 'Vietnam' OR 'West Bank* Gaza' OR 'Yemen' OR 'Zambia' OR 'Zimbabwe').mp. [mp=title, abstract, original title, name

of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

8. Developing countries/ OR Argentina/ OR Bolivia/ OR Brazil/ OR Colombia/ OR Ecuador/ OR Guyana/ OR Paraguay/ OR Peru/ OR Suriname/ OR Venezuela/ OR exp Latin America/ OR exp Caribbean Region/ OR exp Central America/ OR exp Africa/ OR esp Central Asia/ OR exp Northern Asia/ OR Cambodia/ OR Timor-Leste/ OR Indonesia/ OR Laos/ OR Malaysia/ OR Myanmar/ OR Philippines/ OR Thailand/ OR Vietnam/ OR Bangladesh/ OR Buthan/ OR exp India/ OR Nepal/ OR Pakistan/ OR Sri Lanka/ OR Afghanistan/ OR Iran/ OR Iraq/ OR Jordan/ OR Lebanon/ OR Syria/ OR Turkey/ OR Yemen/ OR exp China/ OR Mongolia/ OR Democratic People's Republic of Korea/ OR Balkan Peninsula/ OR Albania/ OR Bosnia and Herzegovina/ OR Bulgaria/ OR Kosovo/ OR Macedonia/ OR Moldova/ OR Montenegro/ OR exp Republic of Belarus OR Romania/ OR exp Russia/ OR Serbia/ OR Ukraine/ OR exp Transcaucasia/ OR Comoros/ OR Madagascar/ OR Mauritius/ OR Indonesia/ OR Fiji/ OR Papua New Guinea/ OR Vanuatu/ OR Palau/ OR exp Samoa/ OR Tonga/ OR Cuba/ OR Dominica/ OR Dominican Republic/ OR Grenada/ OR Haiti/ OR Jamaica/ OR St. Lucia/ OR St. Vincent and the Grenadines/

9. 7 {or/and} 8

10. 3 and 6 and 9

11. Limit 10 to (full text and yr="2007 -Current" and (English or Portuguese or Spanish))

Search	Free text words - Portuguese (MeSH terms only available in English)
#1	<p>“atenção primár* saúde” OR “cuidado* primár*” OR “saúde primár*” OR “gestão* saúde” OR “manej* saúde” OR “interven* saúde* primár*” OR “program* preven*” OR “interven* preven*” OR “interven* precoce*” OR “estratégi* saúde primár*” OR “promoç* d* saúde” OR “saúde integral*” OR “saúde* comuni*” OR “saúde* família*” OR “saúde públic*” OR “sistema* saúde*” OR “trabalhador* saúde” OR “agente* saúde” OR “profissão* saúde” OR “polític* saúde” OR “cuidado* pré-nata*” OR “ambulatór* pré-nata*” OR “saúde básic*” OR “atenç* básic*” OR “centro* saúde” OR “posto* saúde” OR “unidade* saúde”</p>
#2	<p>“violen* parceir*” OR “abus* parceir*” OR “violen* conjug*” OR “abus* conjug*” OR “agress* parceir*” OR “violen* contra* mulher*” OR “mulher* espancada*” OR “violen* namor*” OR “abus* namor*” OR “violen* gênero” OR “abus* gênero”</p>
#3	<p>“país* renda baixa* média*” OR “país* baixa* média* renda*” OR “país* baixa* renda*” OR “país* renda* média” OR “país* subdesenvolv*” OR “país* em desenvolvimento” OR “país* terceiro mundo” OR “naç* renda baixa* média*” OR “naç* terceiro mundo” OR “naç* subdesenvolv*” OR “naç* menos desenvolvid*” OR “naç* baix* desenvolv*” OR “naç* em desenvolvimento” OR “país* menos desenvolvid*” OR “país* emergente*” OR “país* pobre*” OR “naç* pobre*” OR “mundo em desenvolvimento” OR “mundo subdesenvolvido” OR “mundo emergente” OR “naç* emergente* OR “América Latin*” OR "América Central" OR "América do Sul" OR “Carib*” OR "África*" OR "Ásia*" OR "Pacífico*" OR “Oceania” OR "Oriente Médio" OR "Afeganistão" OR "Albânia" OR "Argélia" OR "Samoa Americana" OR "Angola" OR "Argentina" OR "Armênia" OR "Azerbaijão" OR "Bangladesh" OR "Bielorrússia" OR "Belize" OR "Benin" OR "Butão" OR "Bolívia" OR "Bósnia* Herzegovina" OR "Botswana" OR "Brasil" OR "Bulgária" OR “Burkina Faso" OR "Burundi" OR "Cabo Verde" OR "Camboja" OR "Camarões" OR "República Centro-Africana" OR "Chade" OR "China" OR "Colômbia" OR "Comores" OR "Congo, Dem* Rep*" OR "Congo,</p>


<p>Rep*" OR "Costa Rica" OR "Costa do Marfim" OR "Cuba" OR "Djibouti" OR "Dominica" OR "República Dominicana" OR "Ecuador" OR "Egito" OR "El Salvador" OR "Guiné Equatorial" OR "Eritreia" OR "Etiópia" OR "Fiji" OR "Gabão" OR "Gâmbia" OR "Geórgia" OR "Gana" OR "Granada" OR "Guatemala" OR "Guiné" OR "Guiné-Bissau" OR "Guiana" OR "Haiti" OR "Honduras" OR "Índia" OR "Indonésia" OR "Irã" OR "Iraque" OR "Jamaica" OR "Jordânia" OR "Cazaquistão" OR "Quênia" OR "Kiribati" OR "Coréia, Rep* Dem*" OR "Coréia do Norte" OR "Kosovo" OR "Quirguistão" OR "Laos" OR "Líbano" OR "Lesoto" OR "Libéria" OR "Líbia" OR "Macedônia" OR "Madagascar" OR "Malawi" OR "Malásia" OR "Maldivas" OR "Mali" OR "Ilhas Marshall" OR "Mauritânia" OR "Mauríci*" OR "México" OR "Micronésia" OR "Moldávia" OR "Mongólia" OR "Montenegro" OR "Marrocos" OR "Moçambique" OR "Mianmar" OR "Namíbia" OR "Nepal" OR "Nicarágua" OR "Níger" OR "Nigéria" OR "Paquistão" OR "Palau" OR "Panamá" OR "Papua Nova Guiné" OR "Paraguai" OR "Peru" OR "Filipinas" OR "Romênia" OR "Federação Russa" OR "Rússia" OR "Ruanda" OR "Samoa" OR "São Tomé e Príncipe" OR "Senegal" OR "Sérvia" OR "Serra Leoa" OR "Ilhas Salomão" OR "Somália" OR "África do Sul" OR "Sudão do Sul" OR "Sri Lanka" OR "St. Lucia" OR "São. Vicente e Granadinas" OR "Sudão" OR "Suriname" OR "Suazilândia" OR "República Árabe da Síria" OR "Síria" OR "Tajiquistão" OR "Tanzânia" OR "Tailândia" OR "Timor-Leste" OR "Timor* Leste" OR "Togo" OR "Tonga" OR "Tunísia" OR "Turquia" OR "Turcomenistão" OR "Tuvalu" OR "Uganda" OR "Ucrânia" OR "Uzbequistão" OR "Vanuatu" OR "Venezuela" OR "Vietn*" OR "Cisjordânia" OR "Gaza" OR "Palestina" OR "Iêmen" OR "Zâmbia" OR "Zimbábue"</p>
--

Search	Free text words - Spanish (MeSH terms only available in English)
#1	<p>“atenci* primar* salud” OR “atenci* primar*” OR “cuidado* primar*” OR “salud primar*” OR “gestión* salud” OR “manej* salud” OR “interven* primar* salud*” OR “program* OR interven*” OR “interven* tempran*” OR “estrateg* salud primar*” OR “promoc* salud” OR “salud integral*” OR “salud* comuni*” OR “salud* famili*” OR “salud public*” OR “sistema* salud” OR “trabajad* salud” OR “agente* salud” OR “profession* salud” OR “politic* salud” OR “cuidado prenatal*” OR “clínica* prenatal*” OR “salud basic*” OR “atenci* basic*” OR “primer nivel de atención” OR “centro* de salud” OR “puesto* de salud” OR “posta* médica*”</p>
#2	<p>“violencia* pareja*” OR “abuso* pareja*” OR “violencia conyug*” OR “abuso conyug*” OR “daño* pareja*” OR “violencia* contra la* mujer*” OR “abus* contra la* mujer*” OR “mujer* golpeada*” OR “mujer* maltratada*” OR “violencia* contra la* enamora*” OR “abus* contra la* enamora*” OR “violencia de género” OR “abuso de género” OR “violencia de* compañer* íntim*” OR “mujer* violentada*”</p>
#3	<p>“país* con ingreso mediano* bajo*” OR “país* con ingreso bajo*” OR “país* subdesarrollado*” OR “país* en desarrollo*” OR “país* tercer mundo” OR “nación* con ingreso mediano* bajo*” OR “nación* del tercer mundo” OR “nación* subdesarrollada*” OR “nación* menos desarroll*” OR “nación* con bajo desarroll*” OR “nación* en desarrollo” OR “país* menos desarroll*” OR “país* menos desarroll*” OR “país* emergente*” OR “nación* emergente*” OR “mundo emergente” OR “mundo subdesarrollado” OR “país* en vías de desarrollo” OR “Caribe” OR “América Latina*” OR “América del Sur” OR “Sudamérica” OR “África*” OR “Asia*” OR “Pacífico” OR “Oriente Medio” OR “Afganistán” OR “Albania” OR “Argelia” OR “Angola” OR “Argentina” OR “Samoa Americana” OR “Armenia” OR “Azerbaiyán” OR “Bangladesh” OR “Bielorrusia” OR “Belice” OR “Benin” OR “Bolivia” OR “Bosnia* Herzegovina” OR</p>

"Botswana" OR "Brasil" OR "Bulgaria" OR "Burkina Faso" OR "Burundi" OR "Bhutan"
 OR "Cabo Verde" OR "Camboya" OR "Camerún" OR "República Centroafricana"
 OR "Chad" OR "China" OR "Costa Rica" OR "Costa de Marfil" OR "Cuba" OR
 "Djibouti" OR "Dominica" OR "Costa Rica" OR "Colombia" OR "Comoras" OR "Congo,
 Rep*" OR "República Dominicana" OR "Ecuador" OR "Egipto" OR "El Salvador" OR
 "Guinea Ecuatorial" OR "Eritrea" OR "Etiopía" OR "Fiji" OR "Gabón" OR "Georgia"
 OR "Gambia" OR "Ghana" OR "Grenada" OR "Guatemala" OR "Guinea" OR "Guinea-
 Bissau" OR "Guyana" OR "Haití" OR "Honduras" OR "India" OR "Indonesia" OR "Iran"
 OR "Irak" OR "Jamaica" OR "Jordania" OR "Kazajstán" OR "Kenia" OR "Kiribati" OR
 "Corea, República Democrática" OR "Corea del Norte" OR "Kosovo" OR "Laos" OR
 "Líbano" OR "Lesotho" OR "Liberia" OR "Libia" OR "Macedonia" OR "Madagascar"
 OR "Malawi" OR "Malasia" OR "Maldivas" OR "Mali" OR "Islas Marshall" OR
 "Mauritania" OR "Maurici*" OR "México" OR "Micronesia" OR "Moldavia" OR
 "Mongolia" OR "Montenegro" OR "Marruecos" OR "Mozambique" OR "Myanmar" OR
 "Namibia" OR "Nepal" OR "Nicaragua" OR "Níger" OR "Nigeria" OR "Pakistán" OR
 "Palau" OR "Panamá" OR "Papúa Nueva Guinea" OR "Paraguay" OR "Perú" OR
 "Filipinas" OR "Rumania" OR "Rusia" OR "Rwanda" OR "Samoa" OR "Santo Tomé y
 Príncipe" OR "Senegal" OR "Serbia" OR "Sierra Leona" OR "Somalia" OR "Sudáfrica"
 OR "Sudán del Sur" OR "Sri Lanka" OR "St. Lucia" OR "Siria" OR "Tayikistán" OR
 "Tanzania" OR "Tailandia" OR "Timor Oriental" OR "República Democrática del
 Congo" OR "Tonga" OR "Túnez" OR "Turquía" OR "Turkmenistán" OR "Tuvalu" OR
 "Uganda" OR "Ucrania" OR "Uzbekistán" OR "Vanuatu" OR "Venezuela" OR
 "Vietnam" OR "Cisjordania*" OR "Gaza" OR "Palestina" OR "Yemen" OR "Zambia"
 OR "Zimbabwe"

This search strategy can be adapted and modified according to each electronic database.

Appendix 3 -PRISMA Flow Diagram: flow of information through different phases of a systematic review



45 Source: Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-
 46 analyses: the PRISMA statement. PLoS Med 2009;6:e1000097 doi:10.1371/journal.pmed.1000097 [published
 47 Online: 21 July 2009].

Appendix 4 - Data Items

1. General Information and characteristics of the studies

- a. Author's name
- b. Journal
- c. Year of publication
- d. Country of the intervention
- e. Context (urban/rural)
- f. Type of service/setting
- g. Participants (e.g. workers, users - victims, family members, perpetrators)

2. Methodology

- a. Study design
- b. Type of intervention
- c. Sample/number of participants
- d. Year(s) when intervention was conducted
- e. Data collection
- f. Measures
- g. Analysis
- h. Ethics clearance

3. Impacts/outcomes of the intervention for survivors:

- a. IPV rates
- b. health (e.g. physical, mental)
- c. safety (e.g. safety plans)
- d. wellbeing (e.g. quality of life)
- e. children (e.g. children's health and wellbeing)
- f. Other Impacts/outcomes (if described)
- g. Barriers and facilitators for survivors (if investigated)

4. Impacts/outcomes of the intervention for PHC workers:

- a. Types of workers (e.g. nurses, community health workers, receptionists)
- b. Worker's' role in the intervention
- c. Measures of impacts/outcomes concerned to workers
- d. Barriers and facilitators for workers (if described)

5. Role of the PHC services and public health systems to improve survivors' healthcare:

- a. Measures of impacts/outcomes of the intervention for services/systems
- b. Impacts/outcomes of the intervention for policies and organizational structure
- c. Articulation with other levels of care in the healthcare system (e.g. hospital, emergency, etc.)
- d. Articulation with other sectors beyond public health (e.g. police, justice, housing, etc.)
- e. Costs
- f. Sustainability
- g. Barriers and facilitators for services/systems (if described)

6. Other relevant information

Appendix 1 - PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page number
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not an update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	PROSPERO CRD42017069261
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	11
Sponsor	5b	Provide name for the review funder and/or sponsor	11
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	11
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	3,4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4, 5, 6, 7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Detailed on Appendix 2
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	8 and Appendix 4
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5, 6
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	7, 8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8,9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	8, 9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Not applicable
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8, 9
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Not applicable
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix 2 - General Search Strategy

1. ('primary health care*' or 'primary care*' or 'primary health*' or 'primary health care interven*' or 'health* manag*' or 'care manag*' or 'primary health interven*' or 'prevent* program*' or 'prevent* interven*' or 'early interven*' or 'primary health*' or 'strateg*' or 'health promot*' or 'comprehensive health*' or 'community health*' or 'famil* health*' or 'public health*' or 'health* system*' or 'health* worker*' or 'health* profession*' or 'health* polic*' or 'antenatal car*' or 'antenatal clinic*' or 'basic health*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

2. Primary Health Care/ or Public Health/ or Health Policy/ or Health Promotion/ or Health Personnel/ or Developing Countries/

3. 1 {or/and} 2

4. ('partner violen*' or 'partner abus*' or 'spouse violen*' or 'spouse abus*' or 'partner harm*' or 'violen* against wom*' or 'battered women' or 'dating violen*' or 'dating abus*' or 'gender based violen*' or 'gender based abus*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

5. Intimate Partner Violence/ or Battered Women/

6. 4 {or/and} 5

7. ('low* middle* incom* countr*' OR 'low* incom* countr*' OR 'middle* incom* countr*' OR 'underdevelop* countr*' OR 'developing countr*' OR 'third* world countr*' OR 'low* middle* income* nation*' OR 'third*world* nation*' OR 'underdevelop* nation*' OR 'less* developed nation*' OR 'low* income nation*' OR 'developing nation*' OR 'least* developed countr*' OR 'emerg* countr*' OR 'less-developed countr*' OR 'developing world*' OR 'undeveloped world*' OR 'emerg* world' OR 'Latin* America*' OR 'Central* America*' OR 'Caribbean' OR 'South* America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle* East*' OR 'Latin* America*' OR 'Central America*' OR 'South America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle East*' OR 'Afghanistan' OR 'Albania' OR 'Algeria' OR 'American Samoa' OR 'Angola' OR 'Argentina' OR 'Armenia' OR 'Azerbaijan' OR 'Bangladesh' OR 'Belarus' OR 'Belize' OR 'Benin' OR 'Bhutan' OR 'Bolivia' OR 'Bosnia*Herzegovina' OR 'Botswana' OR 'Brazil' OR 'Bulgaria' OR 'Burkina Faso' OR 'Burundi' OR 'Cabo Verde' OR 'Cambodia' OR 'Cameroon' OR 'Central African Republic' OR 'Chad' OR 'China' OR 'Colombia' OR 'Comoros' OR 'Congo, Dem* Rep*' OR 'Congo, Rep*' OR 'Costa Rica' OR 'Cote d'Ivoire' OR 'Cuba' OR 'Djibouti' OR 'Dominica' OR 'Dominican Republic' OR 'Ecuador' OR 'Egypt' OR 'El Salvador' OR 'Equatorial Guinea' OR 'Eritrea' OR 'Ethiopia' OR 'Fiji' OR 'Gabon' OR 'Gambia' OR 'Georgia' OR 'Ghana' OR 'Grenada' OR 'Guatemala' OR 'Guinea' OR 'Guinea-Bissau' OR 'Guyana' OR 'Haiti' OR 'Honduras' OR 'India' OR 'Indonesia' OR 'Iran' OR 'Iraq' OR 'Jamaica' OR 'Jordan' OR 'Kazakhstan' OR 'Kenya' OR 'Kiribati' OR 'Korea, Dem* People's Rep*' OR 'North Korea' OR 'Kosovo' OR 'Kyrgyz' OR 'Lao' OR 'Lebanon' OR 'Lesotho' OR 'Liberia' OR 'Libya' OR 'Macedonia' OR 'Madagascar' OR 'Malawi' OR 'Malaysia' OR 'Maldives' OR 'Mali' OR 'Marshall Islands' OR 'Mauritania' OR 'Mauritius' OR Mexico' OR 'Micronesia' OR 'Moldova' OR 'Mongolia' OR 'Montenegro' OR 'Morocco' OR 'Mozambique' OR 'Myanmar' OR 'Namibia' OR 'Nepal' OR 'Nicaragua' OR Niger' OR 'Nigeria' OR 'Pakistan' OR 'Palau' OR 'Palestine' OR 'Panama' OR 'Papua New Guinea' OR 'Paraguay' OR 'Peru' OR 'Philippines' OR 'Romania' OR 'Russian Federation' OR 'Russia' OR 'Rwanda' OR 'Samoa' OR 'Sao Tome and Principe' OR 'Senegal' OR 'Serbia' OR 'Sierra Leone' OR 'Solomon Islands' OR 'Somalia' OR 'South Africa' OR 'South Sudan' OR 'Sri Lanka' OR 'St. Lucia' OR 'St. Vincent and the Grenadines' OR 'Sudan' OR 'Suriname' OR 'Swaziland' OR 'Syrian Arab Republic' OR 'Syria' OR 'Tajikistan' OR 'Tanzania' OR 'Thailand' OR 'Timor-Leste' OR 'East Timor' OR 'Togo' OR 'Tonga' OR 'Tunisia' OR 'Turkey' OR 'Turkmenistan' OR 'Tuvalu' OR 'Uganda' OR 'Ukraine' OR 'Uzbekistan' OR 'Vanuatu' OR 'Venezuela' OR 'Vietnam' OR 'West Bank* Gaza' OR 'Yemen' OR 'Zambia' OR 'Zimbabwe').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word,

rare disease supplementary concept word, unique identifier, synonyms]

8. Developing countries/ OR Argentina/ OR Bolivia/ OR Brazil/ OR Colombia/ OR Ecuador/ OR Guyana/ OR Paraguay/ OR Peru/ OR Suriname/ OR Venezuela/ OR exp Latin America/ OR exp Caribbean Region/ OR exp Central America/ OR exp Africa/ OR esp Central Asia/ OR exp Northern Asia/ OR Cambodia/ OR Timor-Leste/ OR Indonesia/ OR Laos/ OR Malaysia/ OR Myanmar/ OR Philippines/ OR Thailand/ OR Vietnan/ OR Bangladesh/ OR Buthan/ OR exp India/ OR Nepal/ OR Pakistan/ OR Sri Lanka/ OR Afghanistan/ OR Iran/ OR Iraq/ OR Jordan/ OR Lebanon/ OR Syria/ OR Turkey/ OR Yemen/ OR exp China/ OR Mongolia/ OR Democratic People’s Republic of Korea/ OR Balkan Peninsula/ OR Albania/ OR Bosnia and Herzegovina/ OR Bulgaria/ OR Kosovo/ OR Macedonia/ OR Moldova/ OR Montenegro/ OR exp Republic of Belarus OR Romania/ OR exp Russia/ OR Serbia/ OR Ukraine/ OR exp Transcaucasia/ OR Comoros/ OR Madagascar/ OR Mauritius/ OR Indonesia/ OR Fiji/ OR Papua New Guinea/ OR Vanuatu/ OR Palau/ OR exp Samoa/ OR Tonga/ OR Cuba/ OR Dominica/ OR Dominican Republic/ OR Grenada/ OR Haiti/ OR Jamaica/ OR St. Lucia/ OR St. Vincent and the Grenadines/

9. 7 {or/and} 8

10. 3 and 6 and 9

11. Limit 10 to (full text and yr="2007 -Current" and (English or Portuguese or Spanish))

Search	Free text words - Portuguese (MeSH terms only available in English)
#1	<p>“atenção primár* saúde” OR “cuidado* primár*” OR “saúde primár*” OR “gestão* saúde” OR “manej* saúde” OR “interven* saúde* primár*” OR “program* preven*” OR “interven* preven*” OR “interven* precoce*” OR “estratégi* saúde primár*” OR “promoç* d* saúde” OR “saúde integral*” OR “saúde* comuni*” OR “saúde* família*” OR “saúde públic*” OR “sistema* saúde*” OR “trabalhador* saúde” OR “agente* saúde” OR “profissiona* saúde” OR “polític* saúde” OR “cuidado* pré-nata*” OR “ambulator* pré-nata*” OR “saúde básic*” OR “atenç* básic*” OR “centro* saúde” OR “posto* saúde” OR “unidade* saúde”</p>
#2	<p>“violen* parceir*” OR “abus* parceir*” OR “violen* conjug*” OR “abus* conjug*” OR “agress* parceir*” OR “violen* contra* mulher*” OR “mulher* espancada*” OR “violen* namor*” OR “abus* namor*” OR “violen* gênero” OR “abus* gênero”</p>
#3	<p>“país* renda baixa* média*” OR “país* baixa* média* renda*” OR “país* baixa* renda*” OR “país* renda* média” OR “país* subdesenvolv*” OR “país* em desenvolvimento” OR “país* terceiro mundo” OR “naç* renda baixa* média*” OR “naç* terceiro mundo” OR “naç* subdesenvolv*” OR “naç* menos desenvolvid*” OR “naç* baix* desenvolv*” OR “naç* em desenvolvimento” OR “país* menos desenvolvid*” OR “país* emergente*” OR “país* pobre*” OR “naç* pobre*” OR “mundo em desenvolvimento” OR “mundo subdesenvolvido” OR “mundo emergente” OR “naç* emergente* OR “América Latin*” OR "América Central" OR "América do Sul" OR “Carib*” OR “África*” OR “Ásia*” OR “Pacífico*” OR “Oceania” OR "Oriente Médio" OR "Afeganistão" OR "Albânia" OR "Argélia" OR "Samoa Americana" OR "Angola" OR "Argentina" OR "Armênia" OR "Azerbaijão" OR "Bangladesh" OR "Bielorrússia" OR "Belize" OR "Benin" OR "Butão" OR "Bolívia" OR "Bósnia* Herzegovina" OR "Botswana" OR "Brasil" OR "Bulgária" OR “Burkina Faso” OR "Burundi" OR "Cabo Verde" OR "Camboja" OR "Camarões" OR "República Centro-Africana" OR "Chade" OR "China" OR "Colômbia" OR "Comores" OR "Congo, Dem* Rep*” OR "Congo, Rep*” OR "Costa Rica" OR "Costa do Marfim" OR "Cuba" OR "Djibouti” OR</p>


<p>"Dominica" OR "República Dominicana" OR "Equador" OR "Egito" OR "El Salvador" OR "Guiné Equatorial" OR "Eritreia" OR "Etiópia" OR "Fiji" OR "Gabão" OR "Gâmbia" OR "Geórgia" OR "Gana" OR "Granada" OR "Guatemala" OR "Guiné" OR "Guiné-Bissau" OR "Guiana" OR "Haiti" OR "Honduras" OR "Índia" OR "Indonésia" OR "Irã" OR "Iraque" OR "Jamaica" OR "Jordânia" OR "Cazaquistão" OR "Quênia" OR "Kiribati" OR "Coréia, Rep* Dem*" OR "Coréia do Norte" OR "Kosovo" OR "Quirguistão" OR "Laos" OR "Líbano" OR "Lesoto" OR "Libéria" OR "Líbia" OR "Macedônia" OR "Madagascar" OR "Malawi" OR "Malásia" OR "Maldivas" OR "Mali" OR "Ilhas Marshall" OR "Mauritânia" OR "Mauríci*" OR "México" OR "Micronésia" OR "Moldávia" OR "Mongólia" OR "Montenegro" OR "Marrocos" OR "Moçambique" OR "Mianmar" OR "Namíbia" OR "Nepal" OR "Nicarágua" OR Níger " OR "Nigéria" OR "Paquistão" OR "Palau" OR "Panamá" OR "Papua Nova Guiné" OR "Paraguai" OR "Peru" OR "Filipinas" OR "Romênia" OR "Federação Russa" OR "Rússia" OR "Ruanda" OR "Samoa" OR "São Tomé e Príncipe" OR "Senegal" OR "Sérvia" OR "Serra Leoa" OR "Ilhas Salomão" OR "Somália" OR "África do Sul" OR "Sudão do Sul" OR "Sri Lanka" OR "St. Lucia" OR "São. Vincente e Granadinas" OR "Sudão" OR "Suriname" OR "Suazilândia" OR "República Árabe da Síria" OR "Síria" OR "Tajiquistão" OR "Tanzânia" OR "Tailândia" OR "Timor-Leste" OR "Timor* Leste" OR "Togo" OR "Tonga" OR "Tunísia" OR "Turquia" OR "Turcomenistão" OR "Tuvalu" OR "Uganda" OR "Ucrânia" OR "Uzbequistão" OR "Vanuatu" OR "Venezuela" OR "Vietn*" OR "Cisjordânia" OR "Gaza" OR "Palestina" OR "Iêmen" OR "Zâmbia" OR "Zimbábue"</p>

Search	Free text words - Spanish (MeSH terms only available in English)
#1	<p>“atenci* primar* salud” OR “atenci* primar*” OR “cuidado* primar*” OR “salud primar*” OR “gestion* salud” OR “manej* salud” OR “interven* primar* salud*” OR “program* OR interven*” OR “interven* tempran*” OR “estrateg* salud primar*” OR “promoc* salud” OR “salud integral*” OR “salud* comuni*” OR “salud* famili*” OR “salud public*” OR “sistema* salud” OR “trabajad* salud” OR “agente* salud” OR “profession* salud” OR “politic* salud” OR “cuidado prenatal*” OR “clínica* prenatal*” OR “salud basic*” OR “atenci* basic*” OR “primer nivel de atención” OR “centro* de salud” OR “puesto* de salud” OR “posta* médica*”</p>
#2	<p>“violen* pareja*” OR “abuso* pareja*” OR “violencia conyug*” OR “abuso conyug*” OR “daño* pareja*” OR “violen* contra la* mujer*” OR “abus* contra la* mujer*” OR “mujer* golpeada*” OR “mujer* maltratada*” OR “violen* contra la* enamora*” OR “abus* contra la* enamora*” OR “violencia de género” OR “abuso de género” OR “violencia de* compañer* íntim*” OR “mujer* violentada*”</p>
#3	<p>“país* con ingreso mediano* bajo*” OR “país* con ingreso bajo* OR “país* subdesarrollado*” OR “país* en desarrollo*” OR “país* tercer mundo” OR “nacion* con ingreso mediano* bajo*” OR “nacion* del tercer mundo” OR “nacion* subdesarrollada*” OR “nacion* menos desarroll*” OR “nacion* con bajo desarroll*” OR “nacion* en desarrollo” OR “país* menos desarroll*” OR “país* menos desarroll*” OR “país* emergente*” OR “nacion* emergente*” OR “mundo emergente” OR “mundo subdesarrollado” OR “país* en vías de desarrollo” OR “Caribe” OR “América Latina*” OR “América del Sur” OR “Sudamérica” “África*” OR “Asia*” OR “Pacífico” OR “Oriente Medio” OR “Afganistán” OR “Albania” OR “Argelia” OR “Angola” OR “Argentina” OR “Samoa Americana” OR “Armenia” OR “Azerbaiyán” OR “Bangladesh” OR “Bielorrusia” OR “Belice” OR “Benin” OR “Bolivia” OR “Bosnia* Herzegovina” OR “Botswana” OR “Brasil” OR “Bulgaria” OR “Burkina Faso” OR “Burundi” OR “Bhutan”</p>

OR "Cabo Verde" OR "Camboya" OR "Camerún" OR "República Centroafricana" OR "Chad" OR "China" OR "Costa Rica" OR "Costa de Marfil" OR "Cuba" OR "Djibouti" OR "Dominica" OR "Costa Rica" OR "Colombia" OR "Comoras" OR "Congo, Rep*" OR "República Dominicana" OR "Ecuador" OR "Egipto" OR "El Salvador" OR "Guinea Ecuatorial" OR "Eritrea" OR "Etiopía" OR "Fiji" OR "Gabón" OR "Georgia" OR "Gambia" OR "Ghana" OR "Grenada" OR "Guatemala" OR "Guinea" OR "Guinea-Bissau" OR "Guyana" OR "Haití" OR "Honduras" OR "India" OR "Indonesia" OR "Iran" OR "Irak" OR "Jamaica" OR "Jordania" OR "Kazajstán" OR "Kenia" OR "Kiribati" OR "Corea, República Democrática" OR "Corea del Norte" OR "Kosovo" OR "Laos" OR "Líbano" OR "Lesotho" OR "Liberia" OR "Libia" OR "Macedonia" OR "Madagascar" OR "Malawi" OR "Malasia" OR "Maldivas" OR "Mali" OR "Islas Marshall" OR "Mauritania" OR "Maurici*" OR "México" OR "Micronesia" OR "Moldavia" OR "Mongolia" OR "Montenegro" OR "Marruecos" OR "Mozambique" OR "Myanmar" OR "Namibia" OR "Nepal" OR "Nicaragua" OR "Níger" OR "Nigeria" OR "Pakistán" OR "Palau" OR "Panamá" OR "Papúa Nueva Guinea" OR "Paraguay" OR "Perú" OR "Filipinas" OR "Rumania" OR "Rusia" OR "Rwanda" OR "Samoa" OR "Santo Tomé y Príncipe" OR "Senegal" OR "Serbia" OR "Sierra Leona" OR "Somalia" OR "Sudáfrica" OR "Sudán del Sur" OR "Sri Lanka" OR "St. Lucia" OR "Siria" OR "Tayikistán" OR "Tanzania" OR "Tailandia" OR "Timor Oriental" OR "República Democrática del Congo" OR "Tonga" OR "Túnez" OR "Turquía" OR "Turkmenistán" OR "Tuvalu" OR "Uganda" OR "Ucrania" OR "Uzbekistán" OR "Vanuatu" OR "Venezuela" OR "Vietnam" OR "Cisjordania*" OR "Gaza" OR "Palestina" OR "Yemen" OR "Zambia" OR "Zimbabwe"

This search strategy can be adapted and modified according to each electronic database.

Appendix 3 -PRISMA Flow Diagram: flow of information through different phases of a systematic review



48 Source: Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-
49 analyses: the PRISMA statement. PLoS Med 2009;6:e1000097 doi:10.1371/journal.pmed.1000097 [published
50 Online: 21 July 2009].
51
52
53
54
55
56
57
58
59
60

Appendix 4 - Data Items

1. General Information and characteristics of the studies

- a. Author's name
- b. Journal
- c. Year of publication
- d. Country of the intervention
- e. Context (urban/rural)
- f. Type of service/setting
- g. Participants (e.g. workers, users - victims, family members, perpetrators)

2. Methodology

- a. Study design
- b. Type of intervention
- c. Sample/number of participants
- d. Year(s) when intervention was conducted
- e. Data collection
- f. Measures
- g. Analysis
- h. Ethics clearance

3. Impacts/outcomes of the intervention for survivors:

- a. IPV rates
- b. health (e.g. physical, mental)
- c. safety (e.g. safety plans)
- d. wellbeing (e.g. quality of life)
- e. children (e.g. children's health and wellbeing)
- f. Other Impacts/outcomes (if described)
- g. Barriers and facilitators for survivors (if investigated)

4. Impacts/outcomes of the intervention for PHC workers:

- a. Types of workers (e.g. nurses, community health workers, receptionists)
- b. Worker's role in the intervention
- c. Measures of impacts/outcomes concerned to workers
- d. Barriers and facilitators for workers (if described)

5. Role of the PHC services and public health systems to improve survivors' healthcare:

- a. Measures of impacts/outcomes of the intervention for services/systems
- b. Impacts/outcomes of the intervention for policies and organizational structure
- c. Articulation with other levels of care in the healthcare system (e.g. hospital, emergency, etc.)
- d. Articulation with other sectors beyond public health (e.g. police, justice, housing, etc.)
- e. Costs
- f. Sustainability
- g. Barriers and facilitators for services/systems (if described)

6. Other relevant information

BMJ Open

Voices from low-and-middle-income countries: a systematic review protocol of primary health care interventions within public health systems addressing intimate partner violence against women

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019266.R1
Article Type:	Protocol
Date Submitted by the Author:	21-Nov-2017
Complete List of Authors:	Signorelli, Marcos; Universidade Federal do Parana, Collective Health Hillel, Stav; La Trobe University - Melbourne Campus, Library de Oliveira, Daniel; Universidade Federal do Rio Grande do Sul, Collective Health Ayala Quintanilla, Beatriz; La Trobe University College of Science Health and Engineering, Judith Lumley Centre; Peruvian National Institute of Health, Lima Hegarty, Kelsey; University of Melbourne, Dept of General Practice; The Royal Women's Hospital Taft, Angela; La Trobe University, Mother and Child Health Research
Primary Subject Heading:	Public health
Secondary Subject Heading:	Health services research, General practice / Family practice
Keywords:	PUBLIC HEALTH, INTIMATE PARTNER VIOLENCE, LOW-AND-MIDDLE-INCOME COUNTRIES, PRIMARY CARE, SYSTEMATIC REVIEW

SCHOLARONE™
Manuscripts

Title: Voices from low-and-middle-income countries: a systematic review protocol of primary health care interventions within public health systems addressing intimate partner violence against women

Authors:

1. Signorelli, MC.

Ph.D. in Public Health

Postdoctoral Fellow, La Trobe University

Lecturer, Federal University of Parana

Rua Jaguariaíva, 512. Matinhos/PR - Brazil

T:+55 41 3511 8326

E: signorelli.marcos@gmail.com

2. Hillel, S.

Senior Learning Advisor (Library), La Trobe University

Plenty Road & Kingsbury Drive, Bundoora VIC 3086

T: 03 9479 6097

E: s.hillel@latrobe.edu.au

3. Oliveira, DC.

PhD in Health Sciences

Lecturer, Federal University of Rio Grande do Sul

Porto Alegre/RS, Brazil

T: +55 51 98344 5848

E: daniel.canavese@gmail.com

4. Ayala Quintanilla, BP.

Ph.D. candidate, Judith Lumley Centre, La Trobe University

Melbourne/VIC, Australia

T: 03 9479 8784

E: 17801497@students.latrobe.edu.au

5. Hegarty K,

Ph.D. in Preventive Medicine

Professor of Family Violence Prevention, The Royal Women's Hospital, Melbourne

Professor, Department of General Practice, The University of Melbourne

Melbourne/VIC, Australia

E: k.hegarty@unimelb.edu.au

6. Taft A.

Ph.D. in Public Health

1
2
3 Professor, Judith Lumley Centre, La Trobe University

4 Melbourne/VIC, Australia

5
6 E: a.taft@latrobe.edu.au
7

8
9 Word count: 4847 (excluding title, abstract, strengths & limitations, references and appendixes)
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Intimate partner violence (IPV) considerably harms the health, safety, and wellbeing of women. In response, public health systems around the globe have been gradually implementing strategies. In particular, low- and middle-income countries (LMIC) have been developing innovative interventions in primary health care (PHC) addressing the problem. This paper describes a protocol for a systematic review of studies addressing the impacts and outcomes of PHC centre interventions addressing IPV against women from LMIC.

Methods and analysis: A systematic search for studies will be conducted in African Index Medicus, Africa Portal Digital Library, CINAHL, Embase, Index Medicus for the South-East Asia Region, IndMed, LILACS, Medecins Sans Frontieres, Medline, Minority Health and Health Equity Archive, ProQuest, PsychInfo, SciELO, and Social Policy and Practice. Studies will be in English, Spanish, and Portuguese, published between 2007 and 2017, addressing IPV against women from LMIC, whose data quantitatively report on the impacts and outcomes for survivors and/or workers and/or public health systems pre- and post-intervention. Two trilingual reviewers will independently screen for study eligibility and data extraction, and a librarian will cross check for compliance. Risk of bias and quality assessment of studies will be measured according to: (1) the Cochrane Collaboration's tool for assessing risk of bias for randomised controlled trials; and (2) the methodological index for non-randomised studies (MINORS). Data will be analysed and summarised using meta-analysis and narrative description of the evidence across studies. This systematic review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.

Ethics and dissemination: This systematic review will be based on published studies, thus not requiring ethical approval. Findings will be presented in conferences and published in a peer-reviewed journal.

Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42017069261

Strengths and limitations of this study

- The comprehensive search strategy of this systematic review will allow identification of a range of interventions from different LMIC published in peer-reviewed journals in English, Spanish and Portuguese.
- This protocol is co-authored by researchers from LMIC, who are native-speakers of the languages included in this systematic review. This can strengthen the review process given linguistic and cultural aspects of the diverse studies will be recognised.
- The review intends to promote voices from LMIC, who otherwise may go unheard, given relative financial barriers of LMIC research institutions and the publication bias to English.
- It is expected that there will be some variability related to methodological diversity and outcomes of the reviewed studies, due to the broad scope of PHC interventions addressing IPV, making it challenging to compare outcomes across different scenarios.

INTRODUCTION

Intimate partner violence (IPV) is the most prevalent type of violence against women^{1,2}. The World Health Organization (WHO) estimates that one in three women experience physical or sexual IPV during their lifetime¹. IPV against women is defined by the WHO as any behaviour within an intimate relationship that causes physical damage, psychological or sexual abuse to a woman in the

relationship, including physical assault, psychological abuse, forced intercourse, and other forms of sexual coercion and of controlling behaviours².

The consequences of IPV for women's health have been extensively described, demonstrating that abused women have poorer health compared to women who have never been abused^{3 4}. There are a wide range of consequences including: a) physical health, such as injuries, traumas, cardiovascular effects⁵; b) mental health, including depression, anxiety, post-traumatic stress disorder (PTSD), alcohol and drug abuse and suicide⁶; c) sexual and reproductive health, including sexually transmitted diseases (STD), miscarriage, reduced contraception and sexual autonomy⁷. The consequences are not only for women, but also for their children, including increased risk for low birth weight, preterm delivery, and neonatal death⁷.

IPV against women is a common problem all over the world, but multicountry studies, such as the one developed by the WHO³, which compared ten different income range countries, reveal higher prevalence and the worst consequences for women from low-and-middle-income countries (LMIC)³. The World Bank classifies all countries by income, based on the gross national income (GNI) per capita per year⁸. This review comprises the LMIC, which are the countries with a GNI per capita \leq US\$12,475 per year, as of March, 2017.

IPV has been recognized as a public health issue and included in the agendas of public health systems worldwide². The WHO Sustainable Development Goal number 5 aims to achieve gender equality and empower all women and girls. It includes two subitems targeting violence specifically: 5.1 'End all forms of discrimination against all women and girls everywhere'; and 5.2 'Eliminate all forms of violence against all women and girls in the public and private spheres, including trafficking and sexual and other types of exploitation'⁹. The World Health Assembly in 2016 recommended actions¹⁰, such as: strengthening health system leadership to prevent interpersonal violence and improving health workers'/providers' capacity to respond to violence, in particular against women and children.

Each country responds differently to the problem in the health arena, and exchanging experiences can be a significant opportunity to foster local debate and action¹¹. This systematic review focuses on experiences conducted within public health systems, and more specifically, in primary health care setting. Public health systems consist of systems provided and/or funded by governments aiming to promote the health of their citizens, considering health as a human right^{12 13}. Public health systems intend to ensure that everyone has access to appropriate, efficient and quality health services, aiming for equity of access to health services for all populations¹⁴. Public health systems can have a crucial role in a multisector response to IPV, but it requires changes in the systems, coordinated planning and actions, for example, targeting different levels of care, such as primary health care (PHC)¹⁵.

Primary health care can be considered both a philosophy and a system response to reducing health inequities and ameliorating the effects of disadvantage¹⁶. PHC is the first level of contact individuals, families and communities have with the healthcare system¹⁷. As it has a broad scope, in this study we adopt a more recent definition of PHC, consisting of 'a socially appropriate, universally accessible, scientifically sound first level care provided by health services and systems with a suitably trained workforce comprised of multidisciplinary teams supported by integrated referral systems in a way that: gives priority to those most in need and addresses health inequalities; maximises community and individual self-reliance, participation and control; and involves collaboration and partnership with other sectors to promote public health'¹⁸.

Globally, numerous LMIC are developing innovative interventions addressing IPV against women with a focus on PHC¹⁹. However, some of these interventions may go unnoticed by mainstream researchers from high-income countries. Our hypothesis is that this could be related to different factors, such as: 1) the high costs for the development of complex interventions considered the gold standard of research (e.g.: randomised controlled trials); 2) high publication costs in prestigious academic journals, accompanied by high standards which are difficult to achieve by LMIC researchers given scarce resources, and; 3) linguistic barriers, as writing papers in English—the dominant language for publication in prestigious journals of high income countries—can be very expensive for non-English speaking researchers. However, such interventions developed in LMIC are

not necessarily low quality studies. Indeed, they can be scalable and generalisable, affording insights for public health systems in other contexts, including both high-income countries and LMIC.

While previous reviews have been published in this area, they are either not systematic reviews^{20 21}, or if systematic, did not focus solely on LMIC²². Or if focusing on LMIC, did not target specifically health systems nor PHC²³. Moreover, none of the extant systematic reviews include studies in Spanish or Portuguese, nor searched regional databases for literature. Thus, this will be the first systematic review addressing IPV interventions in PHC from LMIC to include studies in English, Spanish, and Portuguese, retrieved from, amongst others, regional databases.

The focus of this systematic review on PHC rather than the whole health system, because PHC is usually the first point of entrance for women in the health system, especially in LMIC. From our previous studies²⁴⁻²⁶ and the literature²², we noticed that PHC approaches to deal with IPV have some particularities, which are different from other levels of care, such as hospital settings, for example. The routines, professional training and strategies to prevent or reduce IPV can be very different across different levels of care, especially regarding low-and-middle-income contexts^{21 23}. Consequently, the target of this review on PHC is to bring visibility to strategies conducted in this specific level of care, which is the least expensive and with greatest coverage²⁷⁻²⁹. We consider that this is of particular interest for LMIC, that could have an opportunity to manage the problem in the PHC system, with fewer resources and covering more people, compared to other levels of care. We believe that evidence from interventions developed within primary health systems from certain LMIC could provide reflections to support public health policy makers and managers to implement feasible interventions in greater scale and/or other countries.

REVIEW QUESTIONS

- 1) To what extent do primary health care interventions within public health systems improve the health, safety and wellbeing of women survivors of IPV in LMIC?
- 2) What are the main impacts and outcomes of these interventions for PHC workers' practices and the sustainability of these practices for public health systems?

OBJECTIVES

To conduct a systematic review of quantitative studies focusing on primary health care interventions in LMIC, with the aim of prevention or reduction of IPV alongside the improvement of survivors' health, safety and wellbeing.

METHODS

This systematic review will be conducted and reported according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P)^{30 31}, which includes the use of the PRISMA-P checklist (see appendix 1), following methodological approaches published in previous studies³². The review will be published according to the recommended items for systematic reviews based on the PRISMA statement³². This review will also be informed by the guidelines of the Cochrane Handbook³³ for systematic reviews of interventions to reinforce rigour along the process.

Study registration

This systematic review is registered in the PROSPERO International Prospective Register of Systematic Reviews with number CRD42017069261.
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017069261)

Types of studies

In this review we will include studies with quantitative pre-and-post evaluation concerning PHC interventions of IPV against women from LMIC developed within their respective public health systems. For the purposes of this review, we will consider interventions as proposed by Blankenship³⁴, consisting on actions generally taken by outsiders (often read experts), but including individuals and collectives who take actions on their own behalf, purposefully to address a particular risk or disease. This can include individual interventions (focused on individuals' knowledge, attitudes and behaviors) or structural interventions (aiming to change structural factors, such as economic, politico-legal, physical, and social environment). The interventions can include the following experimental and quasi-experimental approaches: randomised controlled trial, non-randomised controlled trial, and quasi-experimental, but also include pre-post designs. We will not include observational studies, qualitative methodologies, or prevalence studies.

We license the inclusion of a broad type of interventions by acknowledging the relatively poor funding allotted to research in LMIC. While cognisant that RCTs, for example, are the gold standard in research, and further, that the Cochrane Collaboration largely recommends methodologically-randomised studies to be the focus of review, we argue that filtering solely for such studies would miss many interventions employed in LMIC - the economic capital in LMIC simply does not allow for it. Given our aim is to "hear voices for the LMIC," and encouraged by the Cochrane's recognition that non-RCTs may be more appropriate at times³³, our approach is expansive.

Types of participants and settings

We recognise that the definition of PHC can be very complex, and subject to conceptual debate. For the purpose of this review, we will include any healthcare facility considered as a Primary Healthcare Centre, but restricted to public health services from LMIC. The WHO³⁵ defines Primary Healthcare Centres as centres providing services which are usually the first point of contact with a health professional. They include services provided by general practitioners, dentists, community nurses, pharmacists and midwives, among others. It can include, for example, General Practice Clinics, Community Based Units, Basic Health Units, Family Health Strategy, Primary Care Home Visits, Day Care Centres, Multicentre Health Clinics and One Stop Crisis Center. This review will not include studies of interventions conducted outside of PHC centres and from the public health systems, such as media campaigns, interventions in schools or in hospitals, which are considered tertiary level of care.

Interventions in PHC for IPV usually focus on workers' strategies to improve survivors' health. This can include healthcare professionals, paraprofessionals, managers and other workers, like receptionists, for example. By 'survivors'¹⁰ we mean any adult women older than 16 years-old affected by IPV and part of the population of an intervention of PHC centres from low- and middle-income countries. This review will target interventions addressed to adult women, because of their particularities, approaches and outcomes, which may be different from those targeting children. The impacts of interventions for children will not be excluded, but they can provide additional information. Consequently, the impact on children will be included in secondary outcomes.

Intervention(s), exposure

The types of interventions may include: studies about implementation of public policies to reduce/prevent IPV targeting PHC centres; education/training of PHC workers to manage IPV survivors; screening or case-finding IPV in PHC settings; strategies for organizational changes in PHC centres aiming to improve survivors' health, safety or wellbeing; therapeutic interventions for IPV focused in PHC centres.

Comparator(s)/control

Studies with all types of control conditions will also be included in this review, including no treatment group, treatment as usual, or comparison. We will not limit our review only to studies that compare active interventions with a control condition.

Types of outcomes measures

Primary outcomes

Primary outcomes will include the impacts and outcomes of the intervention for:

- a) IPV, measured by validated instruments (such as the Composite Abuse Scale³⁶, Index of Spouse Abuse³⁷, etc.) or self-reported IPV (even if adopting unvalidated scale).
- b) women's perceived and diagnosed physical, psychological or sexual health and wellbeing, using validated instruments for each domain (such as General Health Questionnaire³⁸, Center for Epidemiologic Studies Depression Scale - CESD³⁹ - Post Traumatic Stress Disorder Checklist⁴⁰, the Short-Form Health Survey - SF-36⁴¹, etc.).
- c) women's safety, adopting validated or unvalidated measures (such as safety plans, danger assessment⁴², etc.).
- d) PHC workers' practices, that may include identification of abuse by workers; information-giving or safety planning and referral to other services within the public health system (such as hospitals, emergency settings, etc.) or to other services beyond the public health (such as family violence support agencies, police, justice, housing, etc.);

Other outcomes (secondary outcomes)

Secondary outcomes will include the impacts and outcomes of the intervention for:

- a) children's health and wellbeing, considering intimate partner abuse also affects children, assessments through validated instruments regarding children's health and wellbeing will also be reviewed (such as Child Health Questionnaire – CHQ⁴³, etc.).
- b) changes in public health systems' policies and practices, considering policies about system and worker responses; training programs in place; routine data collection; guidelines for workers; funding allocation and cost/benefit measures; and sustainability, considering for this analysis only follow-up evaluations conducted no less than 12 months after the conclusion of the intervention.

Search strategy

A systematic search will be conducted for literature published between 1 January 2007 and 31 July 2017. We choose this time range given the first multi-country study addressing our question in the context of LMIC was published in 2006³.

The following databases will be searched: African Index Medicus, Africa Portal Digital Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Index Medicus for the South-East Asia Region, IndMed, Latin American and Caribbean Health Science Information Database (LILACS), Medecins Sans Frontieres, Medline, Minority Health and Health Equity Archive, ProQuest, PsychInfo, Scientific Electronic Library Online (SciELO), Social Policy and Practice.

This review considers studies published in English, Spanish, and Portuguese, given these are the official languages of 69 of the 145 LMIC (World Bank). Earlier systematic reviews²³ concerning interventions to IPV in LMIC did not consider articles in languages other than English. This review team consists of authors native in the three languages included, minimizing bias related to language. Accordingly, keywords and MeSH will be translated from English by author 1 and reviewed by authors 3 (to Portuguese) and 4 (to Spanish).

1
2
3 Authors 1 and 2 independently consider keywords and MeSH headings. Any discrepancies are
4 subjected to justification. The general search strategy is shown in appendix 2, and will be adapted and
5 modified appropriately according to each database.

6 **Data collection and analysis**

7 **Eligibility criteria of the studies:**

8
9 The inclusion criteria will be:

- 10 1. Studies from the eligible bibliographic databases with selected (combination of) terms and
11 keywords (appendix 2).
- 12 2. Peer reviewed articles published in English, Spanish or Portuguese
- 13 3. Studies published between 2007 and 2017.
- 14 4. Interventions related to IPV conducted in PHC centres within the public health systems from
15 LMIC.
- 16 5. Quantitative pre-and-post studies assessing the impacts and outcomes for survivors (adult
17 women) and/or workers and/or public health systems.
- 18 6. Primary data collection or existing data set analysis.

19
20
21
22 The exclusion criteria will be:

- 23 1. Studies published in languages other than English, Spanish or Portuguese.
- 24 2. Interventions from non-LMIC or not-conducted in PHC centres or conducted only in the
25 private health system.
- 26 3. Studies that did not quantitatively assess pre-and-post interventions or that did not describe
27 the impacts and outcomes for survivors (adult women), workers or public health systems.
- 28 4. Studies that do not include a primary or secondary outcome related to interventions for IPV
29 against adult women.
- 30 5. Grey literature, including any study protocols, theses, case reports, letters, opinions,
31 editorials, weekly reports, policy documents, congress abstracts, theoretical papers,
32 observational studies, qualitative studies or reviews.
- 33 6. Studies published in 2006 or earlier or with the full text not available in the eligible databases.
- 34 7. Duplicate studies that have used the same study population or data. In this case, it will be used
35 only the most recent or relevant publication, for researches published in more than one
36 journal.

37 38 39 40 41 **Data management of the studies**

42
43 COVIDENCE (www.covidence.org) will be employed to manage retrieved studies and to conduct the
44 systematic review process. The bibliographic software platform Endnote (online version
45 www.myendnoteweb.com) will also be used to manage and store relevant studies for this review.
46 These softwares will remove duplicates thereby cleaning the sample. A checklist will be developed
47 based on the eligibility criteria of this review. The flow diagram showing the main steps of this
48 systematic review is available on Appendix 3, following the PRISMA statement^{30,31}.

49 50 **Data selection of the studies**

51
52 The first step consists of the screening of potential studies. This will be done independently and
53 blinded by two investigators fluent in the three languages included in this review (Authors 1 and 3).
54 They will analyse titles and abstracts of all non-duplicate papers from the electronic search, assessing
55 their eligibility. This process of double blinded screening was previously described⁴⁴ for rigorous
56 systematic reviews. Some papers may not describe precisely their abstracts, so a careful search is
57

1
2
3 proposed to maximise the inclusion of studies. Following Ayala-Quintanilla and colleagues⁴⁴, if there
4 is uncertainty about the inclusion of a certain study in this step, that study will be temporarily
5 included and will proceed to the next step for more evaluation. Considering all the selected databases
6 provide an English version of their titles and abstracts, a librarian (Author 2) will cross-check this first
7 step, comparing the independent results obtained from each investigator and ensuring that all steps
8 were conducted in compliance with the protocol. If there is any uncertainty between the resultant
9 studies, the librarian will seek for an opinion from one of the advisors (Authors 5 and 6) that compose
10 this review team.

11
12 The second step consists of examining the full version of all selected studies from the first step,
13 concerning the selection criteria. Two investigators will analyse independently all the articles for each
14 language. The librarian will double check it this process.

15
16 The final list of selected studies will be reviewed independently. For each exclusion, justification will
17 be documented. The results will be compared by the librarian, and any disagreements will be
18 discussed and if necessary, consultation with a third author will occur to reach the consensus.

19 **Appraisal/assessment of the risk of bias of the included studies**

20
21 It is expected that eligible studies will vary according to their methodological approach. There is a
22 vast range of tools to assess the quality and bias of studies. Nevertheless, evaluating such biases and
23 qualities is a challenging task and there is no consensus to conduct it.

24
25 Grading of Recommendations, Assessment, Development and Evaluation (GRADE)⁴⁵ and the
26 EQUATOR (Enhancing the Quality and Transparency of health Research) Network⁴⁶ provide support
27 with guidelines and tools to evaluate the studies, rating up according to the level of evidence.

28
29 In this review, to minimize the risk of bias and evaluate the quality of evidence of each article
30 included, we will adopt: 1) the Cochrane Collaboration's tool for assessing risk of bias for randomised
31 controlled trials⁴⁷; 2) the Methodological index for non-randomised studies (MINORS)⁴⁸ to assess
32 non-randomised interventional studies. This process will be independently performed by different
33 authors (two authors for articles written in English, two for studies written in Portuguese, and two for
34 articles in Spanish) and any disagreement will be discussed and resolved by a third author, if needed.

35 **Data extraction**

36
37 For this third step, three investigators (Authors 1, 3 and 4) will independently and blindly extract all
38 data items (see appendix 4) of each included study with a standardised data collection form. The first
39 author will extract data from studies in English and Portuguese. The third author will extract data
40 from studies in Portuguese and Spanish, while the fourth author will collect from Spanish and
41 English. All extracted data will be converted into English by authors for articles in Spanish or
42 Portuguese, to allow the analysis by all authors in a common language for all. To guarantee that no
43 errors will be made, the librarian (Author 2) will randomly cross-check these data. Any disagreements
44 will be resolved by consensus between the two authors collecting each language and a third author
45 (Author 5 or 6) can be arbitrator if consensus is not reached, following other systematic review
46 protocols⁴⁴.

47 **Data items**

48
49 The descriptive items that will be collected are (see appendix 4): (1) general information and
50 characteristics of the study, including the country/place, type of service where it was conducted, target
51 participants and their main sociodemographic characteristics; (2) methodological characteristics,
52 including the type of method and how data/information were collected, components that were
53 analysed/; (3) impacts and outcomes for survivors, including IPV rates, women's health, safety and
54 wellbeing and also impacts for their children; (4) impacts and outcomes for PHC workers, including
55
56
57
58
59

1
2
3 types of workers, their roles and concerning measures; (5) impacts and outcomes for the public health
4 systems, including measures of articulation with other levels of care (for example, hospitals,
5 emergency units, intensive care units, etc) and other sectors beyond the public health (for example,
6 housing, financing, police, justice, social services, etc), and also evaluation of costs and sustainability
7 of the intervention. For items 3, 4 and 5, we will also collect information about barriers and
8 facilitators for each of the three components (survivors, workers and systems), if available.
9

10 11 **Data synthesis and analysis**

12
13 Data extracted will be analysed and summarised aiming to answer the research questions. Data will be
14 summarised according to the outcomes: 1) for survivors, including their health, safety and wellbeing
15 as well as impacts on IPV rates; 2) for PHC workers' practices considering their role to improve
16 survivors' health care, and 3) for public health systems, including evaluation of costs and
17 sustainability.
18

19 When appropriate, a meta-analysis can be conducted, if a sufficient number of trials are identified
20 with sufficient homogeneity. The meta-analysis will be conducted with aggregate data, rather than at
21 the individual participant level. Continuous and categorical variables will be summarised according to
22 the presentation of data of each study. Dichotomous outcome data (yes/no experience of IPV) will be
23 described as risk ratios with their 95% confidence intervals. It will also be indicated if those findings
24 were adjusted for confounders. It is anticipated that there will be some variability of reporting impacts
25 and outcomes of interventions across studies. In this case, a narrative description of the available
26 evidence will be conducted instead. This will consider which results are significant and their
27 association with the outcomes, based on data availability across studies.
28

29 This review will present the results reported in the original studies, however authors may be contacted
30 for relevant primary source of data. As indicated previously, we will calculate data, where possible,
31 using the original information from the study such as for IPV or women's health, safety and
32 wellbeing. In addition, quantitative data from figures can be utilised if there is sufficient information
33 reported/explained in the study.
34

35 Additional data analysis can be made in order to assess the comparisons between studies, if possible.
36 Qualitative synthesis of relevant process evaluations of included studies will be reported descriptively,
37 restricting to qualitative components from eligible quantitative studies.
38

39 For duplicate studies that have used the same study population or data, the most recent or relevant
40 publication will be utilised for studies published in more than one journal, if possible the data will be
41 linked together.
42

43 In summary, data analysis will be performed according to the data availability of eligible studies, and
44 statistical expertise will be consulted as needed. The software STATA (version 15) will be utilised for
45 all the quantitative analyses. We will relatively give more weight in the synthesis to results from
46 studies with stronger design.
47

48 **Cochrane's recommendations for reviews in public health**

49
50 This review will follow some of the Cochrane guidelines for reviews conducted in public health and
51 health promotion scenarios. One of the key points is sustainability, referred by The Cochrane
52 Collaboration Group³³ as an important aspect to be included in systematic reviews in public health
53 contexts, because it is likely to increase the concern of policymakers, practitioners and funders. When
54 sustainability was measured in eligible studies we will look for additional explanations about which
55 outcomes were measured over what period. However, if it was not measured, but authors explore the
56
57
58
59

potential for sustainability it will also be summarised.

Another Cochrane³³ recommendation for systematic reviews in public health is the consideration of applicability and transferability. Applicability refers to how the findings of a given study or review can be translated into specific population or settings. Transferability is also referred as the potential for this translation occurs. If the reviewed studies mention these aspects, they will also be included in the analysis.

Economic evidence

Cochrane³³ recommends the review of economic evidence, because it provides additional information for decision makers, considering not only if a strategy or intervention works, but also whether its adoption will improve the use of resources. The economic issues are not the main objective of this review, therefore, it will not be an inclusion or exclusion criteria, but will compose an additional source of information when mentioned in the studies. We believe this information will be particularly important for LMIC and summary will be presented when described in eligible studies.

PRESENTING AND REPORTING THE RESULTS

The process of selection of eligible studies for the systematic review will follow the flow diagram according to guidelines of the PRISMA-P (appendix 1). The main steps of the review will include: the identification of studies, screening, evaluation according to inclusion/exclusion criteria and analysis of eligible studies. Results will be presented according to the outcomes: for survivors; for PHC workers; and for public health systems. Data will be summarized in tables depending on data from each study, but presenting first author's name, country, year of publication, study design, aims and main outcomes.

POTENTIAL AMENDMENTS

This protocol is designed to guide with rigour all the steps of this systematic review. Amendments are not expected, but if necessary, just in case of any unexpected event, they will be reported in a detailed and consistent way, followed by appropriate justification. The same will be applied to any differences between the protocol and the review. In case of differences, they will be fully described in a specific section of the final review, providing rationale for them.

CONCLUSION AND IMPLICATIONS

Intimate partner violence is one of the main public health problems for women's health, safety and wellbeing. It requires effective and sustainable actions to reduce harm and life-threatening, targeting comprehensive interventions, particularly in primary health care settings in low-and-middle income contexts. This challenge is more severe in developing countries and exchanging effective interventions can be a coordinated way to foster debate and action. This review will systematise the knowledge previously produced, identifying research gaps and opportunities on interventions conducted in LMIC.

IPV is a potentially preventable issue, but its complexity requires the articulation of different sectors (including health systems, education, justice, among others), in different levels (highlighting the key potential role of the primary care level, but connecting to other levels), with collaboration of different actors (such as health professionals, managers, police, etc.) and with different targets (survivors, perpetrators, families, communities, etc.).

Facing this complex scenario, it is significant to recognize the limitations of this review, such as the types of studies included, that do not include all possible methodological approaches conducted in LMIC. Another limitation is the possible diversity of interventions, that can be challenging to be compared and systematised. It could be possible that other relevant studies will be excluded, since this

1
2
3 review includes only studies published in English, Portuguese and Spanish. Another potential
4 limitation may be that funding for rigorous studies of IPV interventions has only been fostered in the
5 past few years, potentially limiting the ability to identify relevant studies in the review time period. In
6 a systematic review, this limitation may also become a study finding, since a dearth of evidence is, in
7 itself, useful to inform the field.

8
9 It is important to mention that the findings of this systematic review will be cautiously interpreted and
10 the conclusions will be presented with parsimony, considering such limitations. This review will only
11 focus in a 'tip of the iceberg', but it can raise questions for future studies with focus, for example, in
12 other levels of care or in other sectors rather than the public health or even including other
13 methodological approaches, such as qualitative studies, which have been extensively reported in
14 LMIC.
15

16 17 **ETHICS AND DISSEMINATION**

18 19 **Ethical issues**

20
21 This systematic review is based on studies previously published and does not include collection of
22 new primary data. Consequently, the host university has stated that is not necessary to obtain ethical
23 clearance.
24

25 26 **Publication Plan**

27
28 This review will be publicized in conferences (preliminary results) and the final article will be
29 published in a peer-reviewed journal. We intend to publish both the protocol and the systematic
30 review in open access journals, aiming to be accessible to investigators currently engaged in
31 interventions in low-and-middle-income countries. This review affords a voice to researchers in the
32 field of IPV who would otherwise go unheard, and provide greater insights into the range of possible
33 interventions for nations facing comparable issues. It is expected that the final publication can support
34 public systems and policies worldwide.
35

36 37 **Author's contributions**

38
39 MS conceived the review. SH, BQ, DO and AT assisted on the design of the study protocol. MS and
40 SH drafted the protocol paper and all authors edited the subsequent versions. AT and KH critically
41 revised the methodology. All authors have reviewed and approved the final version of the text.
42

43
44 **Funding:** This work was supported by the Brazilian CAPES Foundation which funded a scholarship
45 for postdoctoral studies of the first author [Process number 88881.119273/2016-01]. The funder had
46 no role on this protocol development.
47

48
49 **Competing interests:** none
50

51 52 **REFERENCES**

- 53
54 1. WHO. Global and regional estimates of violence against women: prevalence and health effects of
55 intimate partner violence and non-partner sexual violence. Geneva: World Health
56 Organization Department of Reproductive Health and Research, London School of Hygiene
57 and Tropical Medicine, South African Medical Research Council., 2013.
58
59

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
2. Krug EG, Mercy JA, Dahlberg LL, et al. The world report on violence and health. *Lancet* 2002;360(9339):1083-8. doi: 10.1016/S0140-6736(02)11133-0
3. Garcia-Moreno C, Jansen HA, Ellsberg M, et al. Prevalence of intimate partner violence: findings from the WHO multi-country study on women's health and domestic violence. *Lancet* 2006;368(9543):1260-9. doi: 10.1016/S0140-6736(06)69523-8
4. Campbell JC. Health consequences of intimate partner violence. *Lancet* 2002;359(9314):1331-6. doi: 10.1016/S0140-6736(02)08336-8
5. Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate partner violence for men and women. *Am J Prev Med* 2002;23(4):260-8.
6. Dutton MA, Green BL, Kaltman SI, et al. Intimate partner violence, PTSD, and adverse health outcomes. *J Interpers Violence* 2006;21(7):955-68. doi: 10.1177/0886260506289178
7. Sarkar NN. The impact of intimate partner violence on women's reproductive health and pregnancy outcome. *J Obstet Gynaecol* 2008;28(3):266-71. doi: 10.1080/01443610802042415
8. World Bank Country and Lending Groups. Washington: World Bank, 2017.
9. UN. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015:31.
10. Organization WH. Global plan of action to strengthen the role of the health system within a national multisectoral response to address interpersonal violence, in particular against women and girls, and against children. In: research Dfrha, ed. Geneva: WHO, 2016:76.
11. Signorelli MC, Taft A, Pereira PP. Intimate partner violence against women and healthcare in Australia: charting the scene. *Cien Saude Colet* 2012;17(4):1037-48.
12. Carvalho G. A saúde pública no Brasil. *Estudos Avançados* 2013;27(78):20. doi: <http://dx.doi.org/10.1590/S0103-40142013000200002>
13. Aboal-Viñas JL. Salud pública y sistema sanitario. *Gaceta Sanitaria* 2010;4(Supplement 1):7. doi: <https://doi.org/10.1016/j.gaceta.2010.08.003>
14. Naidoo S. The South African national health insurance: a revolution in health-care delivery! *J Public Health (Oxf)* 2012;34(1):149-50. doi: 10.1093/pubmed/fds008
15. García-Moreno C, Hegarty K, d'Oliveira AF, et al. The health-systems response to violence against women. *Lancet* 2015;385(9977):1567-79. doi: 10.1016/S0140-6736(14)61837-7 [published Online First: 2014/11/21]
16. Keleher H. Why primary health care offers a more comprehensive approach to tackling health inequities than primary care. *Australian Journal of Primary Health* 2001;7(2):5.
17. Care ICoPH. Declaration of Alma-Ata. *WHO Chron* 1978;32(11):428-30.
18. (APHCRI) APHCRI. What is primary health care? In: (APHCRI) APHCRI, ed. Canberra: Australian Primary Health Care Research Institute (APHCRI), 2009.
19. Abramsky T, Devries K, Kiss L, et al. Findings from the SASA! Study: a cluster randomized controlled trial to assess the impact of a community mobilization intervention to prevent violence against women and reduce HIV risk in Kampala, Uganda. *BMC Med* 2014;12(1):122. doi: 10.1186/s12916-014-0122-5
20. Colombini M, Mayhew S, Watts C. Health-sector responses to intimate partner violence in low- and middle-income settings: a review of current models, challenges and opportunities. *Bull World Health Organ* 2008;86(8):635-42.
21. Bacchus LJ, Colombini M, Contreras Urbina M, et al. Exploring opportunities for coordinated responses to intimate partner violence and child maltreatment in low and middle income countries: a scoping review. *Psychol Health Med* 2017;22(sup1):135-65. doi: 10.1080/13548506.2016.1274410 [published Online First: 2017/02/02]
22. Bair-Merritt MH, Lewis-O'Connor A, Goel S, et al. Primary care-based interventions for intimate partner violence: a systematic review. *Am J Prev Med* 2014;46(2):188-94. doi: 10.1016/j.amepre.2013.10.001
23. Bourey C, Williams W, Bernstein EE, et al. Systematic review of structural interventions for intimate partner violence in low- and middle-income countries: organizing evidence for prevention. *BMC Public Health* 2015;15:1165. doi: 10.1186/s12889-015-2460-4 [published Online First: 2015/11/23]
24. Hegarty K, Tarzia L, Hooker L, et al. Interventions to support recovery after domestic and sexual violence in primary care. *Int Rev Psychiatry* 2016;28(5):519-32. doi:

- 10.1080/09540261.2016.1210103 [published Online First: 2016/08/09]
25. Taft AJ, Hooker L, Humphreys C, et al. Maternal and child health nurse screening and care for mothers experiencing domestic violence (MOVE): a cluster randomised trial. *BMC Med* 2015;13:150. doi: 10.1186/s12916-015-0375-7 [published Online First: 2015/06/25]
 26. Signorelli MC, Auad D, Pereira PP. Domestic violence against women and professional intervention in primary healthcare: an ethnographic study in Matinhos, Paraná State, Brazil. *Cad Saude Publica* 2013;29(6):1230-40.
 27. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. *Milbank Q* 2005;83(3):457-502. doi: 10.1111/j.1468-0009.2005.00409.x
 28. Kruk ME, Porignon D, Rockers PC, et al. The contribution of primary care to health and health systems in low- and middle-income countries: a critical review of major primary care initiatives. *Soc Sci Med* 2010;70(6):904-11. doi: 10.1016/j.socscimed.2009.11.025 [published Online First: 2010/01/19]
 29. Chan M. Ten years in public health, 2007–2017. In: Organization WH, ed. Geneva: World Health Organization, 2017:152.
 30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/01]
 31. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647. [published Online First: 2015/01/02]
 32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62(10):1006-12. doi: 10.1016/j.jclinepi.2009.06.005 [published Online First: 2009/07/23]
 33. Higgins J, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. West Sussex: The Cochrane Collaboration and John Wiley & Sons, 2008.
 34. Blankenship KM, Friedman SR, Dworkin S, et al. Structural interventions: concepts, challenges and opportunities for research. *J Urban Health* 2006;83(1):59-72. doi: 10.1007/s11524-005-9007-4
 35. WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Appendix 1 Definitions of health-care settings and other related terms. Geneva: World Health Organization, 2009.
 36. Hegarty K, Fracgp, Bush R, et al. The composite abuse scale: further development and assessment of reliability and validity of a multidimensional partner abuse measure in clinical settings. *Violence Vict* 2005;20(5):529-47.
 37. Campbell DW, Campbell J, King C, et al. The reliability and factor structure of the index of spouse abuse with African-American women. *Violence Vict* 1994;9(3):259-74.
 38. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. *Psychol Med* 1979;9(1):139-45.
 39. Eaton W, Smith C, Ybarra M, et al. Center for Epidemiologic Studies Depression Scale: review and revision (CESD and CESD-R). In: Maruish M, ed. *The Use of Psychological Testing for Treatment Planning and Outcomes Assessment*. 3 ed. Mahwah, NJ: Lawrence Erlbaum Associates, Inc 2004.
 40. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary care. *Behav Res Ther* 2005;43(5):585-94. doi: 10.1016/j.brat.2004.04.005
 41. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.
 42. Campbell JC. Nursing assessment for risk of homicide with battered women. *ANS Adv Nurs Sci* 1986;8(4):36-51.
 43. Landgraf J, Abetz L, Ware J. *The Child Health Questionnaire (CHQ) user's manual*. 1st ed. ed. Boston: TheHealth Institute, New England Medical Centre, 1996.
 44. Ayala Quintanilla BP, Taft A, McDonald S, et al. Social determinants and maternal exposure to intimate partner violence of obstetric patients with severe maternal morbidity in the intensive care unit: a systematic review protocol. *BMJ Open* 2016;6(11):e013270. doi:

- 1
2
3 10.1136/bmjopen-2016-013270 [published Online First: 2016/11/28]
4 45. Schünemann HJ, Schünemann AH, Oxman AD, et al. Grading quality of evidence and strength of
5 recommendations for diagnostic tests and strategies. *BMJ* 2008;336(7653):1106-10. doi:
6 10.1136/bmj.39500.677199.AE
7 46. Pandis N, Fedorowicz Z. The international EQUATOR network: enhancing the quality and
8 transparency of health care research. *J Appl Oral Sci* 2011;19(5)
9 47. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk
10 of bias in randomised trials. *BMJ* 2011;343:d5928. [published Online First: 2011/10/18]
11 48. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors):
12 development and validation of a new instrument. *ANZ J Surg* 2003;73(9):712-6.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1 - PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page number
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not an update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	PROSPERO CRD420170692613
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	120
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	124
Sponsor	5b	Provide name for the review funder and/or sponsor	124
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	124
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	3, 4, 5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	45
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4, 5, 6, 7
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	67
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Detailed on Appendix 2
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	78

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	<u>78</u>
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<u>89</u>
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	<u>8,9</u> and Appendix 4
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<u>5,6,7</u>
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<u>7,8,9</u>
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	<u>8,9,10</u>
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	<u>8,9,10</u>
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Not applicable
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<u>8,9,10</u>
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Not applicable
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	<u>8,9</u>

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix 2 - General Search Strategy

1. ('primary health care*' or 'primary care*' or 'primary health*' or 'primary health care interven*' or 'health* manag*' or 'care manag*' or 'primary health interven*' or 'prevent* program*' or 'prevent* interven*' or 'early interven*' or 'primary health*' or 'strateg*' or 'health promot*' or 'comprehensive health*' or 'community health*' or 'famil* health*' or 'public health*' or 'health* system*' or 'health* worker*' or 'health* profession*' or 'health* polic*' or 'antenatal car*' or 'antenatal clinic*' or 'basic health*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

2. Primary Health Care/ or Public Health/ or Health Policy/ or Health Promotion/ or Health Personnel/ or Developing Countries/

3. 1 {or/and} 2

4. ('partner violen*' or 'partner abus*' or 'spouse violen*' or 'spouse abus*' or 'partner harm*' or 'violen* against wom*' or 'battered women' or 'dating violen*' or 'dating abus*' or 'gender based violen*' or 'gender based abus*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

5. Intimate Partner Violence/ or Battered Women/

6. 4 {or/and} 5

7. ('low* middle* incom* countr*' OR 'low* incom* countr*' OR 'middle* incom* countr*' OR 'underdevelop* countr*' OR 'developing countr*' OR 'third* world countr*' OR 'low* middle* income* nation*' OR 'third*world* nation*' OR 'underdevelop* nation*' OR 'less* developed nation*' OR 'low* income nation*' OR 'developing nation*' OR 'least* developed countr*' OR 'emerg* countr*' OR 'less-developed countr*' OR 'developing world*' OR 'undeveloped world*' OR 'emerg* world' OR 'Latin* America*' OR 'Central* America*' OR 'Caribbean' OR 'South* America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle* East*' OR 'Latin* America*' OR 'Central America*' OR 'South America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle East*' OR 'Afghanistan' OR 'Albania' OR 'Algeria' OR 'American Samoa' OR 'Angola' OR 'Argentina' OR 'Armenia' OR 'Azerbaijan' OR 'Bangladesh' OR 'Belarus' OR 'Belize' OR 'Benin' OR 'Bhutan' OR 'Bolivia' OR 'Bosnia*Herzegovina' OR 'Botswana' OR 'Brazil' OR 'Bulgaria' OR 'Burkina Faso' OR 'Burundi' OR 'Cabo Verde' OR 'Cambodia' OR 'Cameroon' OR 'Central African Republic' OR 'Chad' OR 'China' OR 'Colombia' OR 'Comoros' OR 'Congo, Dem* Rep*' OR 'Congo, Rep*' OR 'Costa Rica' OR 'Cote d'Ivoire' OR 'Cuba' OR 'Djibouti' OR 'Dominica' OR 'Dominican Republic' OR 'Ecuador' OR 'Egypt' OR 'El Salvador' OR 'Equatorial Guinea' OR 'Eritrea' OR 'Ethiopia' OR 'Fiji' OR 'Gabon' OR 'Gambia' OR 'Georgia' OR 'Ghana' OR 'Grenada' OR 'Guatemala' OR 'Guinea' OR 'Guinea-Bissau' OR 'Guyana' OR 'Haiti' OR 'Honduras' OR 'India' OR 'Indonesia' OR 'Iran' OR 'Iraq' OR 'Jamaica' OR 'Jordan' OR 'Kazakhstan' OR 'Kenya' OR 'Kiribati' OR 'Korea, Dem* People's Rep*' OR 'North Korea' OR 'Kosovo' OR 'Kyrgyz' OR 'Lao' OR 'Lebanon' OR 'Lesotho' OR 'Liberia' OR 'Libya' OR 'Macedonia' OR 'Madagascar' OR 'Malawi' OR 'Malaysia' OR 'Maldives' OR 'Mali' OR 'Marshall Islands' OR 'Mauritania' OR 'Mauritius' OR Mexico' OR 'Micronesia' OR 'Moldova' OR 'Mongolia' OR 'Montenegro' OR 'Morocco' OR 'Mozambique' OR 'Myanmar' OR 'Namibia' OR 'Nepal' OR 'Nicaragua' OR Niger' OR 'Nigeria' OR 'Pakistan' OR 'Palau' OR 'Palestine' OR 'Panama' OR 'Papua New Guinea' OR 'Paraguay' OR 'Peru' OR 'Philippines' OR 'Romania' OR 'Russian Federation' OR 'Russia' OR 'Rwanda' OR 'Samoa' OR 'Sao Tome and Principe' OR 'Senegal' OR 'Serbia' OR 'Sierra Leone' OR 'Solomon Islands' OR 'Somalia' OR 'South Africa' OR 'South Sudan' OR 'Sri Lanka' OR 'St. Lucia' OR 'St. Vincent and the Grenadines' OR 'Sudan' OR 'Suriname' OR 'Swaziland' OR 'Syrian Arab Republic' OR 'Syria' OR 'Tajikistan' OR 'Tanzania' OR 'Thailand' OR 'Timor-Leste' OR 'East Timor' OR 'Togo' OR 'Tonga' OR 'Tunisia' OR 'Turkey' OR 'Turkmenistan' OR 'Tuvalu' OR 'Uganda' OR 'Ukraine' OR 'Uzbekistan' OR 'Vanuatu' OR 'Venezuela' OR 'Vietnam' OR 'West Bank* Gaza' OR 'Yemen' OR 'Zambia' OR 'Zimbabwe').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word,

rare disease supplementary concept word, unique identifier, synonyms]

8. Developing countries/ OR Argentina/ OR Bolivia/ OR Brazil/ OR Colombia/ OR Ecuador/ OR Guyana/ OR Paraguay/ OR Peru/ OR Suriname/ OR Venezuela/ OR exp Latin America/ OR exp Caribbean Region/ OR exp Central America/ OR exp Africa/ OR esp Central Asia/ OR exp Northern Asia/ OR Cambodia/ OR Timor-Leste/ OR Indonesia/ OR Laos/ OR Malaysia/ OR Myanmar/ OR Philippines/ OR Thailand/ OR Vietnan/ OR Bangladesh/ OR Buthan/ OR exp India/ OR Nepal/ OR Pakistan/ OR Sri Lanka/ OR Afghanistan/ OR Iran/ OR Iraq/ OR Jordan/ OR Lebanon/ OR Syria/ OR Turkey/ OR Yemen/ OR exp China/ OR Mongolia/ OR Democratic People’s Republic of Korea/ OR Balkan Peninsula/ OR Albania/ OR Bosnia and Herzegovina/ OR Bulgaria/ OR Kosovo/ OR Macedonia/ OR Moldova/ OR Montenegro/ OR exp Republic of Belarus OR Romania/ OR exp Russia/ OR Serbia/ OR Ukraine/ OR exp Transcaucasia/ OR Comoros/ OR Madagascar/ OR Mauritius/ OR Indonesia/ OR Fiji/ OR Papua New Guinea/ OR Vanuatu/ OR Palau/ OR exp Samoa/ OR Tonga/ OR Cuba/ OR Dominica/ OR Dominican Republic/ OR Grenada/ OR Haiti/ OR Jamaica/ OR St. Lucia/ OR St. Vincent and the Grenadines/

9. 7 {or/and} 8

10. 3 and 6 and 9

11. Limit 10 to (full text and yr="2007 -Current" and (English or Portuguese or Spanish))

Search	Free text words - Portuguese (MeSH terms only available in English)
#1	<p>“atenção primár* saúde” OR “cuidado* primár*” OR “saúde primár*” OR “gestão* saúde” OR “manej* saúde” OR “interven* saúde* primár*” OR “program* preven*” OR “interven* preven*” OR “interven* precoce*” OR “estratégi* saúde primár*” OR “promoç* d* saúde” OR “saúde integral*” OR “saúde* comuni*” OR “saúde* família*” OR “saúde públic*” OR “sistema* saúde*” OR “trabalhador* saúde” OR “agente* saúde” OR “profissiona* saúde” OR “polític* saúde” OR “cuidado* pré-nata*” OR “ambulator* pré-nata*” OR “saúde básic*” OR “atenç* básic*” OR “centro* saúde” OR “posto* saúde” OR “unidade* saúde”</p>
#2	<p>“violen* parceir*” OR “abus* parceir*” OR “violen* conjug*” OR “abus* conjug*” OR “agress* parceir*” OR “violen* contra* mulher*” OR “mulher* espancada*” OR “violen* namor*” OR “abus* namor*” OR “violen* gênero” OR “abus* gênero”</p>
#3	<p>“país* renda baixa* média*” OR “país* baixa* média* renda*” OR “país* baixa* renda*” OR “país* renda* média” OR “país* subdesenvolv*” OR “país* em desenvolvimento” OR “país* terceiro mundo” OR “naç* renda baixa* média*” OR “naç* terceiro mundo” OR “naç* subdesenvolv*” OR “naç* menos desenvolvid*” OR “naç* baix* desenvolv*” OR “naç* em desenvolvimento” OR “país* menos desenvolvid*” OR “país* emergente*” OR “país* pobre*” OR “naç* pobre*” OR “mundo em desenvolvimento” OR “mundo subdesenvolvido” OR “mundo emergente” OR “naç* emergente* OR “América Latin*” OR "América Central" OR "América do Sul" OR “Carib*” OR “África*” OR “Ásia*” OR “Pacífico*” OR “Oceania” OR "Oriente Médio" OR "Afeganistão" OR "Albânia" OR "Argélia" OR "Samoa Americana" OR "Angola" OR "Argentina" OR "Armênia" OR "Azerbaijão" OR "Bangladesh" OR "Bielorrússia" OR "Belize" OR "Benin" OR "Butão" OR "Bolívia" OR "Bósnia* Herzegovina" OR "Botswana" OR "Brasil" OR "Bulgária" OR “Burkina Faso” OR "Burundi" OR "Cabo Verde" OR "Camboja" OR "Camarões" OR "República Centro-Africana" OR "Chade" OR "China" OR "Colômbia" OR "Comores" OR "Congo, Dem* Rep*” OR "Congo, Rep*” OR "Costa Rica" OR "Costa do Marfim" OR "Cuba" OR "Djibouti” OR</p>


<p>"Dominica" OR "República Dominicana" OR "Equador" OR "Egito" OR "El Salvador" OR "Guiné Equatorial" OR "Eritreia" OR "Etiópia" OR "Fiji" OR "Gabão" OR "Gâmbia" OR "Geórgia" OR "Gana" OR "Granada" OR "Guatemala" OR "Guiné" OR "Guiné-Bissau" OR "Guiana" OR "Haiti" OR "Honduras" OR "Índia" OR "Indonésia" OR "Irã" OR "Iraque" OR "Jamaica" OR "Jordânia" OR "Cazaquistão" OR "Quênia" OR "Kiribati" OR "Coréia, Rep* Dem*" OR "Coréia do Norte" OR "Kosovo" OR "Quirguistão" OR "Laos" OR "Líbano" OR "Lesoto" OR "Libéria" OR "Líbia" OR "Macedônia" OR "Madagascar" OR "Malawi" OR "Malásia" OR "Maldivas" OR "Mali" OR "Ilhas Marshall" OR "Mauritânia" OR "Mauríci*" OR "México" OR "Micronésia" OR "Moldávia" OR "Mongólia" OR "Montenegro" OR "Marrocos" OR "Moçambique" OR "Mianmar" OR "Namíbia" OR "Nepal" OR "Nicarágua" OR "Níger" OR "Nigéria" OR "Paquistão" OR "Palau" OR "Panamá" OR "Papua Nova Guiné" OR "Paraguai" OR "Peru" OR "Filipinas" OR "Romênia" OR "Federação Russa" OR "Rússia" OR "Ruanda" OR "Samoa" OR "São Tomé e Príncipe" OR "Senegal" OR "Sérvia" OR "Serra Leoa" OR "Ilhas Salomão" OR "Somália" OR "África do Sul" OR "Sudão do Sul" OR "Sri Lanka" OR "St. Lucia" OR "São. Vincente e Granadinas" OR "Sudão" OR "Suriname" OR "Suazilândia" OR "República Árabe da Síria" OR "Síria" OR "Tajiquistão" OR "Tanzânia" OR "Tailândia" OR "Timor-Leste" OR "Timor* Leste" OR "Togo" OR "Tonga" OR "Tunísia" OR "Turquia" OR "Turcomenistão" OR "Tuvalu" OR "Uganda" OR "Ucrânia" OR "Uzbequistão" OR "Vanuatu" OR "Venezuela" OR "Vietn*" OR "Cisjordânia" OR "Gaza" OR "Palestina" OR "Iêmen" OR "Zâmbia" OR "Zimbábue"</p>

Search	Free text words - Spanish (MeSH terms only available in English)
#1	<p>“atenci* primar* salud” OR “atenci* primar*” OR “cuidado* primar*” OR “salud primar*” OR “gestion* salud” OR “manej* salud” OR “interven* primar* salud*” OR “program* OR interven*” OR “interven* tempran*” OR “estrateg* salud primar*” OR “promoc* salud” OR “salud integral*” OR “salud* comuni*” OR “salud* famili*” OR “salud public*” OR “sistema* salud” OR “trabajad* salud” OR “agente* salud” OR “profession* salud” OR “politic* salud” OR “cuidado prenatal*” OR “clínica* prenatal*” OR “salud basic*” OR “atenci* basic*” OR “primer nivel de atención” OR “centro* de salud” OR “puesto* de salud” OR “posta* médica*”</p>
#2	<p>“violen* pareja*” OR “abuso* pareja*” OR “violencia conyug*” OR “abuso conyug*” OR “daño* pareja*” OR “violen* contra la* mujer*” OR “abus* contra la* mujer*” OR “mujer* golpeada*” OR “mujer* maltratada*” OR “violen* contra la* enamora*” OR “abus* contra la* enamora*” OR “violencia de género” OR “abuso de género” OR “violencia de* compañer* íntim*” OR “mujer* violentada*”</p>
#3	<p>“país* con ingreso mediano* bajo*” OR “país* con ingreso bajo* OR “país* subdesarrollado*” OR “país* en desarrollo*” OR “país* tercer mundo” OR “nacion* con ingreso mediano* bajo*” OR “nacion* del tercer mundo” OR “nacion* subdesarrollada*” OR “nacion* menos desarroll*” OR “nacion* con bajo desarroll*” OR “nacion* en desarrollo” OR “país* menos desarroll*” OR “país* menos desarroll*” OR “país* emergente*” OR “nacion* emergente*” OR “mundo emergente” OR “mundo subdesarrollado” OR “país* en vías de desarrollo” OR “Caribe” OR “América Latina*” OR “América del Sur” OR “Sudamérica” “África*” OR “Asia*” OR “Pacífico” OR “Oriente Medio” OR “Afganistán” OR “Albania” OR “Argelia” OR “Angola” OR “Argentina” OR “Samoa Americana” OR “Armenia” OR “Azerbaiyán” OR “Bangladesh” OR “Bielorrusia” OR “Belice” OR “Benin” OR “Bolivia” OR “Bosnia* Herzegovina” OR “Botswana” OR “Brasil” OR “Bulgaria” OR “Burkina Faso” OR “Burundi” OR “Bhutan”</p>

<p> OR "Cabo Verde" OR "Camboya" OR "Camerún" OR "República Centroafricana" OR "Chad" OR "China" OR "Costa Rica" OR "Costa de Marfil" OR "Cuba" OR "Djibouti" OR "Dominica" OR "Costa Rica" OR "Colombia" OR "Comoras" OR "Congo, Rep*" OR "República Dominicana" OR "Ecuador" OR "Egipto" OR "El Salvador" OR "Guinea Ecuatorial" OR "Eritrea" OR "Etiopía" OR "Fiji" OR "Gabón" OR "Georgia" OR "Gambia" OR "Ghana" OR "Grenada" OR "Guatemala" OR "Guinea" OR "Guinea- Bissau" OR "Guyana" OR "Haití" OR "Honduras" OR "India" OR "Indonesia" OR "Iran" OR "Irak" OR "Jamaica" OR "Jordania" OR "Kazajstán" OR "Kenia" OR "Kiribati" OR "Corea, República Democrática" OR "Corea del Norte" OR "Kosovo" OR "Laos" OR "Líbano" OR "Lesotho" OR "Liberia" OR "Libia" OR "Macedonia" OR "Madagascar" OR "Malawi" OR "Malasia" OR "Maldivas" OR "Mali" OR "Islas Marshall" OR "Mauritania" OR "Maurici*" OR "México" OR "Micronesia" OR "Moldavia" OR "Mongolia" OR "Montenegro" OR "Marruecos" OR "Mozambique" OR "Myanmar" OR "Namibia" OR "Nepal" OR "Nicaragua" OR "Níger" OR "Nigeria" OR "Pakistán" OR "Palau" OR "Panamá" OR "Papúa Nueva Guinea" OR "Paraguay" OR "Perú" OR "Filipinas" OR "Rumania" OR "Rusia" OR "Rwanda" OR "Samoa" OR "Santo Tomé y Príncipe" OR "Senegal" OR "Serbia" OR "Sierra Leona" OR "Somalia" OR "Sudáfrica" OR "Sudán del Sur" OR "Sri Lanka" OR "St. Lucia" OR "Siria" OR "Tayikistán" OR "Tanzania" OR "Tailandia" OR "Timor Oriental" OR "República Democrática del Congo" OR "Tonga" OR "Túnez" OR "Turquía" OR "Turkmenistán" OR "Tuvalu" OR "Uganda" OR "Ucrania" OR "Uzbekistán" OR "Vanuatu" OR "Venezuela" OR "Vietnam" OR "Cisjordania*" OR "Gaza" OR "Palestina" OR "Yemen" OR "Zambia" OR "Zimbabwe" </p>

This search strategy can be adapted and modified according to each electronic database.

Appendix 3 -PRISMA Flow Diagram: flow of information through different phases of a systematic review



Source: Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097 doi:10.1371/journal.pmed.1000097 [published Online: 21 July 2009].

Appendix 4 - Data Items

1. General Information and characteristics of the studies

- a. Author's name
- b. Journal
- c. Year of publication
- d. Country of the intervention
- e. Context (urban/rural)
- f. Type of service/setting
- g. Participants (e.g. workers, users - victims, family members, perpetrators)

2. Methodology

- a. Study design
- b. Type of intervention
- c. Sample/number of participants
- d. Year(s) when intervention was conducted
- e. Data collection
- f. Measures
- g. Analysis
- h. Ethics clearance

3. Impacts/ and outcomes of the intervention for survivors:

- a. IPV rates
- b. health (e.g. physical, mental)
- c. safety (e.g. safety plans)
- d. wellbeing (e.g. quality of life)
- e. children (e.g. children's health and wellbeing)
- f. Other Impacts/ and outcomes (if described)
- g. Barriers and facilitators for survivors (if investigated)

4. Impacts/ and outcomes of the intervention for PHC workers' practices:

- a. Types of workers (e.g. nurses, community health workers, receptionists)
- b. Worker's role in the intervention
- c. Measures of impacts and /outcomes concerned to workers
- d. Barriers and facilitators for workers (if described)

5. Role of the PHC services and public health systems to improve survivors' healthcare:

- a. Measures of impacts and /outcomes of the intervention for services/systems
- b. Impacts and /outcomes of the intervention for policies and organizational structure
- c. Articulation with other levels of care in the healthcare system (e.g. hospital, emergency, etc.)
- d. Articulation with other sectors beyond public health (e.g. police, justice, housing, etc.)
- e. Costs
- f. Sustainability
- g. Barriers and facilitators for services/systems (if described)

6. Other relevant information

BMJ Open

Voices from low-and-middle-income countries: a systematic review protocol of primary health care interventions within public health systems addressing intimate partner violence against women

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-019266.R2
Article Type:	Protocol
Date Submitted by the Author:	15-Feb-2018
Complete List of Authors:	Signorelli, Marcos; Universidade Federal do Parana, Department of Collective Health Hillel, Stav; La Trobe University - Melbourne Campus, Library de Oliveira, Daniel; Universidade Federal do Rio Grande do Sul, Department of Collective Health Ayala Quintanilla, Beatriz; La Trobe University College of Science Health and Engineering, Judith Lumley Centre; Peruvian National Institute of Health, Lima Hegarty, Kelsey; University of Melbourne, Dept of General Practice; The Royal Women's Hospital Taft, Angela; La Trobe University, Mother and Child Health Research
Primary Subject Heading:	Public health
Secondary Subject Heading:	Health services research, General practice / Family practice
Keywords:	PUBLIC HEALTH, INTIMATE PARTNER VIOLENCE, LOW-AND-MIDDLE-INCOME COUNTRIES, PRIMARY CARE, SYSTEMATIC REVIEW

SCHOLARONE™
Manuscripts

Title: Voices from low-and-middle-income countries: a systematic review protocol of primary health care interventions within public health systems addressing intimate partner violence against women

Authors:

1. Signorelli, MC.

Ph.D. in Public Health

Postdoctoral Fellow, La Trobe University

Lecturer, Federal University of Parana

Rua Jaguariaíva, 512. Matinhos/PR - Brazil

T:+55 41 3511 8326

E: signorelli.marcos@gmail.com

2. Hillel, S.

Senior Learning Advisor (Library), La Trobe University

Plenty Road & Kingsbury Drive, Bundoora VIC 3086

T: 03 9479 6097

E: s.hillel@latrobe.edu.au

3. Oliveira, DC.

PhD in Health Sciences

Lecturer, Federal University of Rio Grande do Sul

Porto Alegre/RS, Brazil

T: +55 51 98344 5848

E: daniel.canavese@gmail.com

4. Ayala Quintanilla, BP.

Ph.D. candidate, Judith Lumley Centre, La Trobe University

Melbourne/VIC, Australia

T: 03 9479 8784

E: 17801497@students.latrobe.edu.au

5. Hegarty K,

Ph.D. in Preventive Medicine

Professor of Family Violence Prevention, The Royal Women's Hospital, Melbourne

Professor, Department of General Practice, The University of Melbourne

Melbourne/VIC, Australia

E: k.hegarty@unimelb.edu.au

6. Taft A.

Ph.D. in Public Health

1
2
3 Professor, Judith Lumley Centre, La Trobe University

4 Melbourne/VIC, Australia

5
6 E: a.taft@latrobe.edu.au
7

8
9 Word count: 4850 (excluding title, abstract, strengths & limitations, references and appendixes)
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Intimate partner violence (IPV) considerably harms the health, safety, and wellbeing of women. In response, public health systems around the globe have been gradually implementing strategies. In particular, low- and middle-income countries (LMIC) have been developing innovative interventions in primary health care (PHC) addressing the problem. This paper describes a protocol for a systematic review of studies addressing the impacts and outcomes of PHC centre interventions addressing IPV against women from LMIC.

Methods and analysis: A systematic search for studies will be conducted in African Index Medicus, Africa Portal Digital Library, CINAHL, Embase, Index Medicus for the South-East Asia Region, IndMed, LILACS, Medecins Sans Frontieres, Medline, Minority Health and Health Equity Archive, ProQuest, PsychInfo, SciELO, and Social Policy and Practice. Studies will be in English, Spanish, and Portuguese, published between 2007 and 2017, addressing IPV against women from LMIC, whose data quantitatively report on the impacts and outcomes for survivors and/or workers and/or public health systems pre- and post-intervention. Two trilingual reviewers will independently screen for study eligibility and data extraction, and a librarian will cross check for compliance. Risk of bias and quality assessment of studies will be measured according to: (1) the Cochrane Collaboration's tool for assessing risk of bias for randomised controlled trials; and (2) the methodological index for non-randomised studies (MINORS). Data will be analysed and summarised using meta-analysis and narrative description of the evidence across studies. This systematic review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.

Ethics and dissemination: This systematic review will be based on published studies, thus not requiring ethical approval. Findings will be presented in conferences and published in a peer-reviewed journal.

Trial registration number: International Prospective Register for Systematic Reviews (PROSPERO) number CRD42017069261

Strengths and limitations of this study

- The comprehensive search strategy of this systematic review will allow identification of a range of interventions from different LMIC published in peer-reviewed journals in English, Spanish and Portuguese.
- This protocol is co-authored by researchers from LMIC, who are native-speakers of the languages included in this systematic review. This can strengthen the review process given linguistic and cultural aspects of the diverse studies will be recognised.
- The review intends to promote voices from LMIC, who otherwise may go unheard, given relative financial barriers of LMIC research institutions and the publication bias to English.
- It is expected that there will be some variability related to methodological diversity and outcomes of the reviewed studies, due to the broad scope of PHC interventions addressing IPV, making it challenging to compare outcomes across different scenarios.

INTRODUCTION

Intimate partner violence (IPV) is the most prevalent type of violence against women^{1,2}. The World Health Organization (WHO) estimates that one in three women experience physical or sexual IPV during their lifetime¹. IPV against women is defined by the WHO as any behaviour within an intimate relationship that causes physical damage, psychological or sexual abuse to a woman in the

1
2
3 relationship, including physical assault, psychological abuse, forced intercourse, and other forms of
4 sexual coercion and of controlling behaviours².

5
6 The consequences of IPV for women's health have been extensively described, demonstrating that
7 abused women have poorer health compared to women who have never been abused^{3 4}. There are a
8 wide range of consequences including: a) physical health, such as injuries, traumas, cardiovascular
9 effects⁵; b) mental health, including depression, anxiety, post-traumatic stress disorder (PTSD),
10 alcohol and drug abuse and suicide⁶; c) sexual and reproductive health, including sexually transmitted
11 diseases (STD), miscarriage, reduced contraception and sexual autonomy⁷. The consequences are not
12 only for women, but also for their children, including increased risk for low birth weight, preterm
13 delivery, and neonatal death⁷.

14
15 IPV against women is a common problem all over the world, but multicountry studies, such as the one
16 developed by the WHO³, which compared ten different income range countries, reveal higher
17 prevalence and the worst consequences for women from low-and-middle-income countries (LMIC)³.
18 The World Bank classifies all countries by income, based on the gross national income (GNI) per
19 capita per year⁸. This review comprises the LMIC, which are the countries with a GNI per capita \leq
20 US\$12,475 per year, as of March, 2017.

21
22 IPV has been recognized as a public health issue and included in the agendas of public health systems
23 worldwide². The WHO Sustainable Development Goal number 5 aims to achieve gender equality and
24 empower all women and girls. It includes two subitems targeting violence specifically: 5.1 'End all
25 forms of discrimination against all women and girls everywhere'; and 5.2 'Eliminate all forms of
26 violence against all women and girls in the public and private spheres, including trafficking and
27 sexual and other types of exploitation'⁹. The World Health Assembly in 2016 recommended actions¹⁰,
28 such as: strengthening health system leadership to prevent interpersonal violence and improving health
29 workers'/providers' capacity to respond to violence, in particular against women and children .

30
31 Each country responds differently to the problem in the health arena, and exchanging experiences can
32 be a significant opportunity to foster local debate and action¹¹. This systematic review focuses on
33 experiences conducted within public health systems, and more specifically, in primary health care
34 setting. Public health systems consist of systems provided and/or funded by governments aiming to
35 promote the health of their citizens, considering health as a human right^{12 13}. Public health systems
36 intend to ensure that everyone has access to appropriate, efficient and quality health services, aiming
37 for equity of access to health services for all populations¹⁴. Public health systems can have a crucial
38 role in a multisector response to IPV, but it requires changes in the systems, coordinated planning and
39 actions, for example, targeting different levels of care, such as primary health care (PHC)¹⁵.

40
41 Primary health care can be considered both a philosophy and a system response to reducing health
42 inequities and ameliorating the effects of disadvantage¹⁶. PHC is the first level of contact individuals,
43 families and communities have with the healthcare system¹⁷. As it has a broad scope, in this study we
44 adopt a more recent definition of PHC, consisting of 'a socially appropriate, universally accessible,
45 scientifically sound first level care provided by health services and systems with a suitably trained
46 workforce comprised of multidisciplinary teams supported by integrated referral systems in a way
47 that: gives priority to those most in need and addresses health inequalities; maximises community and
48 individual self-reliance, participation and control; and involves collaboration and partnership with
49 other sectors to promote public health'¹⁸.

50
51 Globally, numerous LMIC are developing innovative interventions addressing IPV against women
52 with a focus on PHC¹⁹. However, some of these interventions may go unnoticed by mainstream
53 researchers from high-income countries. Our hypothesis is that this could be related to different
54 factors, such as: 1) the high costs for the development of complex interventions considered the gold
55 standard of research (e.g.: randomised controlled trials); 2) high publication costs in prestigious
56 academic journals, accompanied by high standards which are difficult to achieve by LMIC
57 researchers given scarce resources, and; 3) linguistic barriers, as writing papers in English—the
58 dominant language for publication in prestigious journals of high income countries—can be very
59 expensive for non-English speaking researchers. However, such interventions developed in LMIC are
60

not necessarily low quality studies. Indeed, they can be scalable and generalisable, affording insights for public health systems in other contexts, including both high-income countries and LMIC.

While previous reviews have been published in this area, they are either not systematic reviews^{20 21}, or if systematic, did not focus solely on LMIC²². Or if focusing on LMIC, did not target specifically health systems nor PHC²³. Moreover, none of the extant systematic reviews include studies in Spanish or Portuguese, nor searched regional databases for literature. Thus, this will be the first systematic review addressing IPV interventions in PHC from LMIC to include studies in English, Spanish, and Portuguese, retrieved from, amongst others, regional databases.

The focus of this systematic review on PHC rather than the whole health system, because PHC is usually the first point of entrance for women in the health system, especially in LMIC. From our previous studies²⁴⁻²⁶ and the literature²², we noticed that PHC approaches to deal with IPV have some particularities, which are different from other levels of care, such as hospital settings, for example. The routines, professional training and strategies to prevent or reduce IPV can be very different across different levels of care, especially regarding low-and-middle-income contexts^{21 23}. Consequently, the target of this review on PHC is to bring visibility to strategies conducted in this specific level of care, which is the least expensive and with greatest coverage²⁷⁻²⁹. We consider that this is of particular interest for LMIC, that could have an opportunity to manage the problem in the PHC system, with fewer resources and covering more people, compared to other levels of care. We believe that evidence from interventions developed within primary health systems from certain LMIC could provide reflections to support public health policy makers and managers to implement feasible interventions in greater scale and/or other countries.

REVIEW QUESTIONS

- 1) To what extent do primary health care interventions within public health systems improve the health, safety and wellbeing of women survivors of IPV in LMIC?
- 2) What are the main impacts and outcomes of these interventions for PHC workers' practices and the sustainability of these practices for public health systems?

OBJECTIVES

To conduct a systematic review of quantitative studies focusing on primary health care interventions in LMIC, with the aim of prevention or reduction of IPV alongside the improvement of survivors' health, safety and wellbeing.

METHODS

This systematic review will be conducted and reported according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P)^{30 31}, which includes the use of the PRISMA-P checklist (see appendix 1), following methodological approaches published in previous studies³². The review will be published according to the recommended items for systematic reviews based on the PRISMA statement³². This review will also be informed by the guidelines of the Cochrane Handbook³³ for systematic reviews of interventions to reinforce rigour along the process.

Study registration

This systematic review is registered in the PROSPERO International Prospective Register of Systematic Reviews with number CRD42017069261.
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017069261)

Types of studies

In this review we will include studies with quantitative pre-and-post evaluation concerning PHC interventions of IPV against women from LMIC developed within their respective public health systems. For the purposes of this review, we will consider interventions as proposed by Blankenship³⁴, consisting on actions generally taken by outsiders (often read experts), but including individuals and collectives who take actions on their own behalf, purposefully to address a particular risk or disease. This can include individual interventions (focused on individuals' knowledge, attitudes and behaviors) or structural interventions (aiming to change structural factors, such as economic, politico-legal, physical, and social environment). The interventions can include the following experimental and quasi-experimental approaches: randomised controlled trial, non-randomised controlled trial, and quasi-experimental, but also include pre-post designs. We will not include observational studies, qualitative methodologies, or prevalence studies.

We license the inclusion of a broad type of interventions by acknowledging the relatively poor funding allotted to research in LMIC. While cognisant that RCTs, for example, are the gold standard in research, and further, that the Cochrane Collaboration largely recommends methodologically-randomised studies to be the focus of review, we argue that filtering solely for such studies would miss many interventions employed in LMIC - the economic capital in LMIC simply does not allow for it. Given our aim is to "hear voices for the LMIC," and encouraged by the Cochrane's recognition that non-RCTs may be more appropriate at times³³, our approach is expansive.

Types of participants and settings

We recognise that the definition of PHC can be very complex, and subject to conceptual debate. For the purpose of this review, we will include any healthcare facility considered as a Primary Healthcare Centre, but restricted to public health services from LMIC. The WHO³⁵ defines Primary Healthcare Centres as centres providing services which are usually the first point of contact with a health professional. They include services provided by general practitioners, dentists, community nurses, pharmacists and midwives, among others. It can include, for example, General Practice Clinics, Community Based Units, Basic Health Units, Family Health Strategy, Primary Care Home Visits, Day Care Centres, Multicentre Health Clinics and One Stop Crisis Center. This review will not include studies of interventions conducted outside of PHC centres and from the public health systems, such as media campaigns, interventions in schools or in hospitals, which are considered tertiary level of care.

Interventions in PHC for IPV usually focus on workers' strategies to improve survivors' health. This can include healthcare professionals, paraprofessionals, managers and other workers, like receptionists, for example. By 'survivors'¹⁰ we mean any adult women older than 16 years-old affected by IPV and part of the population of an intervention of PHC centres from low- and middle-income countries. This review will target interventions addressed to adult women, because of their particularities, approaches and outcomes, which may be different from those targeting children. The impacts of interventions for children will not be excluded, but they can provide additional information. Consequently, the impact on children will be included in secondary outcomes.

Intervention(s), exposure

The types of interventions may include: studies about implementation of public policies to reduce/prevent IPV targeting PHC centres; education/training of PHC workers to manage IPV survivors; screening or case-finding IPV in PHC settings; strategies for organizational changes in PHC centres aiming to improve survivors' health, safety or wellbeing; therapeutic interventions for IPV focused in PHC centres.

Comparator(s)/control

Studies with all types of control conditions will also be included in this review, including no treatment group, treatment as usual, or comparison. We will not limit our review only to studies that compare active interventions with a control condition.

Types of outcomes measures

Primary outcomes

Primary outcomes will include the impacts and outcomes of the intervention for:

- a) IPV, measured by validated instruments (such as the Composite Abuse Scale³⁶, Index of Spouse Abuse³⁷, etc.) or self-reported IPV (even if adopting unvalidated scale).
- b) women's perceived and diagnosed physical, psychological or sexual health and wellbeing, using validated instruments for each domain (such as General Health Questionnaire³⁸, Center for Epidemiologic Studies Depression Scale - CESD³⁹ - Post Traumatic Stress Disorder Checklist⁴⁰, the Short-Form Health Survey - SF-36⁴¹, etc.).
- c) women's safety, adopting validated or unvalidated measures (such as safety plans, danger assessment⁴², etc.).
- d) PHC workers' practices, that may include identification of abuse by workers; information-giving or safety planning and referral to other services within the public health system (such as hospitals, emergency settings, etc.) or to other services beyond the public health (such as family violence support agencies, police, justice, housing, etc.);

Other outcomes (secondary outcomes)

Secondary outcomes will include the impacts and outcomes of the intervention for:

- a) children's health and wellbeing, considering intimate partner abuse also affects children, assessments through validated instruments regarding children's health and wellbeing will also be reviewed (such as Child Health Questionnaire – CHQ⁴³, etc.).
- b) changes in public health systems' policies and practices, considering policies about system and worker responses; training programs in place; routine data collection; guidelines for workers; funding allocation and cost/benefit measures; and sustainability, considering for this analysis only follow-up evaluations conducted no less than 12 months after the conclusion of the intervention.

Search strategy

A systematic search will be conducted for literature published between 1 January 2007 and 31 July 2017. We choose this time range given the first multi-country study addressing our question in the context of LMIC was published in 2006³.

The following databases will be searched: African Index Medicus, Africa Portal Digital Library, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Index Medicus for the South-East Asia Region, IndMed, Latin American and Caribbean Health Science Information Database (LILACS), Medecins Sans Frontieres, Medline, Minority Health and Health Equity Archive, ProQuest, PsychInfo, Scientific Electronic Library Online (SciELO), Social Policy and Practice.

This review considers studies published in English, Spanish, and Portuguese, given these are the official languages of 69 of the 145 LMIC (World Bank). Earlier systematic reviews²³ concerning interventions to IPV in LMIC did not consider articles in languages other than English. This review team consists of authors native in the three languages included, minimizing bias related to language. Accordingly, keywords and MeSH will be translated from English by author 1 and reviewed by authors 3 (to Portuguese) and 4 (to Spanish).

1
2
3 Authors 1 and 2 independently consider keywords and MeSH headings. Any discrepancies are
4 subjected to justification. The general search strategy is shown in appendix 2, and will be adapted and
5 modified appropriately according to each database.

6 **Data collection and analysis**

7 **Eligibility criteria of the studies:**

8
9 The inclusion criteria will be:

- 10 1. Studies from the eligible bibliographic databases with selected (combination of) terms and
11 keywords (appendix 2).
- 12 2. Peer reviewed articles published in English, Spanish or Portuguese
- 13 3. Studies published between 2007 and 2017.
- 14 4. Interventions related to IPV conducted in PHC centres within the public health systems from
15 LMIC.
- 16 5. Quantitative pre-and-post studies assessing the impacts and outcomes for survivors (adult
17 women) and/or workers and/or public health systems.
- 18 6. Primary data collection or existing data set analysis.

19
20
21
22 The exclusion criteria will be:

- 23 1. Studies published in languages other than English, Spanish or Portuguese.
- 24 2. Interventions from non-LMIC or not-conducted in PHC centres or conducted only in the
25 private health system.
- 26 3. Studies that did not quantitatively assess pre-and-post interventions or that did not describe
27 the impacts and outcomes for survivors (adult women), workers or public health systems.
- 28 4. Studies that do not include a primary or secondary outcome related to interventions for IPV
29 against adult women.
- 30 5. Grey literature, including any study protocols, theses, case reports, letters, opinions,
31 editorials, weekly reports, policy documents, congress abstracts, theoretical papers,
32 observational studies, qualitative studies or reviews.
- 33 6. Studies published in 2006 or earlier or with the full text not available in the eligible databases.
- 34 7. Duplicate studies that have used the same study population or data. In this case, it will be used
35 only the most recent or relevant publication, for researches published in more than one
36 journal.

37 **Data management of the studies**

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

COVIDENCE (www.covidence.org) will be employed to manage retrieved studies and to conduct the systematic review process. The bibliographic software platform Endnote (online version www.myendnoteweb.com) will also be used to manage and store relevant studies for this review. These softwares will remove duplicates thereby cleaning the sample. A checklist will be developed based on the eligibility criteria of this review. The flow diagram showing the main steps of this systematic review is available on Appendix 3, following the PRISMA statement^{30,31}.

51 **Data selection of the studies**

52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

The first step consists of the screening of potential studies. This will be done independently and blinded by two investigators fluent in the three languages included in this review (Authors 1 and 3). They will analyse titles and abstracts of all non-duplicate papers from the electronic search, assessing their eligibility. This process of double blinded screening was previously described⁴⁴ for rigorous systematic reviews. Some papers may not describe precisely their abstracts, so a careful search is

1
2
3 proposed to maximise the inclusion of studies. Following Ayala-Quintanilla and colleagues⁴⁴, if there
4 is uncertainty about the inclusion of a certain study in this step, that study will be temporarily
5 included and will proceed to the next step for more evaluation. Considering all the selected databases
6 provide an English version of their titles and abstracts, a librarian (Author 2) will cross-check this first
7 step, comparing the independent results obtained from each investigator and ensuring that all steps
8 were conducted in compliance with the protocol. If there is any uncertainty between the resultant
9 studies, the librarian will seek for an opinion from one of the advisors (Authors 5 and 6) that compose
10 this review team.

11
12 The second step consists of examining the full version of all selected studies from the first step,
13 concerning the selection criteria. Two investigators will analyse independently all the articles for each
14 language. The librarian will double check it this process.

15
16 The final list of selected studies will be reviewed independently. For each exclusion, justification will
17 be documented. The results will be compared by the librarian, and any disagreements will be
18 discussed and if necessary, consultation with a third author will occur to reach the consensus.

19 **Appraisal/assessment of the risk of bias of the included studies**

20
21 It is expected that eligible studies will vary according to their methodological approach. There is a
22 vast range of tools to assess the quality and bias of studies. Nevertheless, evaluating such biases and
23 qualities is a challenging task and there is no consensus to conduct it.

24
25 Grading of Recommendations, Assessment, Development and Evaluation (GRADE)⁴⁵ and the
26 EQUATOR (Enhancing the Quality and Transparency of health Research) Network⁴⁶ provide support
27 with guidelines and tools to evaluate the studies, rating up according to the level of evidence.

28
29 In this review, to minimize the risk of bias and evaluate the quality of evidence of each article
30 included, we will adopt: 1) the Cochrane Collaboration's tool for assessing risk of bias for randomised
31 controlled trials⁴⁷; 2) the Methodological index for non-randomised studies (MINORS)⁴⁸ to assess
32 non-randomised interventional studies. This process will be independently performed by different
33 authors (two authors for articles written in English, two for studies written in Portuguese, and two for
34 articles in Spanish) and any disagreement will be discussed and resolved by a third author, if needed.

35 **Data extraction**

36
37 For this third step, three investigators (Authors 1, 3 and 4) will independently and blindly extract all
38 data items (see appendix 4) of each included study with a standardised data collection form. The first
39 author will extract data from studies in English and Portuguese. The third author will extract data
40 from studies in Portuguese and Spanish, while the fourth author will collect from Spanish and
41 English. All extracted data will be converted into English by authors for articles in Spanish or
42 Portuguese, to allow the analysis by all authors in a common language for all. To guarantee that no
43 errors will be made, the librarian (Author 2) will randomly cross-check these data. Any disagreements
44 will be resolved by consensus between the two authors collecting each language and a third author
45 (Author 5 or 6) can be arbitrator if consensus is not reached, following other systematic review
46 protocols⁴⁴.

47 **Data items**

48
49 The descriptive items that will be collected are (see appendix 4): (1) general information and
50 characteristics of the study, including the country/place, type of service where it was conducted, target
51 participants and their main sociodemographic characteristics; (2) methodological characteristics,
52 including the type of method and how data/information were collected, components that were
53 analysed/; (3) impacts and outcomes for survivors, including IPV rates, women's health, safety and
54 wellbeing and also impacts for their children; (4) impacts and outcomes for PHC workers, including
55
56
57
58
59

1
2
3 types of workers, their roles and concerning measures; (5) impacts and outcomes for the public health
4 systems, including measures of articulation with other levels of care (for example, hospitals,
5 emergency units, intensive care units, etc) and other sectors beyond the public health (for example,
6 housing, financing, police, justice, social services, etc), and also evaluation of costs and sustainability
7 of the intervention. For items 3, 4 and 5, we will also collect information about barriers and
8 facilitators for each of the three components (survivors, workers and systems), if available.
9

10 11 **Data synthesis and analysis**

12
13 Data extracted will be analysed and summarised aiming to answer the research questions. Data will be
14 summarised according to the outcomes: 1) for survivors, including their health, safety and wellbeing
15 as well as impacts on IPV rates; 2) for PHC workers' practices considering their role to improve
16 survivors' health care, and 3) for public health systems, including evaluation of costs and
17 sustainability.
18

19 When appropriate, a meta-analysis can be conducted, if a sufficient number of trials are identified
20 with sufficient homogeneity. The meta-analysis will be conducted with aggregate data, rather than at
21 the individual participant level. Continuous and categorical variables will be summarised according to
22 the presentation of data of each study. Dichotomous outcome data (yes/no experience of IPV) will be
23 described as risk ratios with their 95% confidence intervals. It will also be indicated if those findings
24 were adjusted for confounders. It is anticipated that there will be some variability of reporting impacts
25 and outcomes of interventions across studies. In this case, a narrative description of the available
26 evidence will be conducted instead. This will consider which results are significant and their
27 association with the outcomes, based on data availability across studies.
28

29 This review will present the results reported in the original studies, however authors may be contacted
30 for relevant primary source of data. As indicated previously, we will calculate data, where possible,
31 using the original information from the study such as for IPV or women's health, safety and
32 wellbeing. In addition, quantitative data from figures can be utilised if there is sufficient information
33 reported/explained in the study.
34

35 Additional data analysis can be made in order to assess the comparisons between studies, if possible.
36 Qualitative synthesis of relevant process evaluations of included studies will be reported descriptively,
37 restricting to qualitative components from eligible quantitative studies.
38

39 For duplicate studies that have used the same study population or data, the most recent or relevant
40 publication will be utilised for studies published in more than one journal, if possible the data will be
41 linked together.
42

43 In summary, data analysis will be performed according to the data availability of eligible studies, and
44 statistical expertise will be consulted as needed. The software STATA (version 15) will be utilised for
45 all the quantitative analyses. We will relatively give more weight in the synthesis to results from
46 studies with stronger design.
47

48 **Cochrane's recommendations for reviews in public health**

49
50 This review will follow some of the Cochrane guidelines for reviews conducted in public health and
51 health promotion scenarios. One of the key points is sustainability, referred by The Cochrane
52 Collaboration Group³³ as an important aspect to be included in systematic reviews in public health
53 contexts, because it is likely to increase the concern of policymakers, practitioners and funders. When
54 sustainability was measured in eligible studies we will look for additional explanations about which
55 outcomes were measured over what period. However, if it was not measured, but authors explore the
56
57
58
59

potential for sustainability it will also be summarised.

Another Cochrane³³ recommendation for systematic reviews in public health is the consideration of applicability and transferability. Applicability refers to how the findings of a given study or review can be translated into specific population or settings. Transferability is also referred as the potential for this translation occurs. If the reviewed studies mention these aspects, they will also be included in the analysis.

Economic evidence

Cochrane³³ recommends the review of economic evidence, because it provides additional information for decision makers, considering not only if a strategy or intervention works, but also whether its adoption will improve the use of resources. The economic issues are not the main objective of this review, therefore, it will not be an inclusion or exclusion criteria, but will compose an additional source of information when mentioned in the studies. We believe this information will be particularly important for LMIC and summary will be presented when described in eligible studies.

PRESENTING AND REPORTING THE RESULTS

The process of selection of eligible studies for the systematic review will follow the flow diagram according to guidelines of the PRISMA-P (appendix 1). The main steps of the review will include: the identification of studies, screening, evaluation according to inclusion/exclusion criteria and analysis of eligible studies. Results will be presented according to the outcomes: for survivors; for PHC workers; and for public health systems. Data will be summarized in tables depending on data from each study, but presenting first author's name, country, year of publication, study design, aims and main outcomes.

POTENTIAL AMENDMENTS

This protocol is designed to guide with rigour all the steps of this systematic review. Amendments are not expected, but if necessary, just in case of any unexpected event, they will be reported in a detailed and consistent way, followed by appropriate justification. The same will be applied to any differences between the protocol and the review. In case of differences, they will be fully described in a specific section of the final review, providing rationale for them.

CONCLUSION AND IMPLICATIONS

Intimate partner violence is one of the main public health problems for women's health, safety and wellbeing. It requires effective and sustainable actions to reduce harm and life-threatening, targeting comprehensive interventions, particularly in primary health care settings in low-and-middle income contexts. This challenge is more severe in developing countries and exchanging effective interventions can be a coordinated way to foster debate and action. This review will systematise the knowledge previously produced, identifying research gaps and opportunities on interventions conducted in LMIC.

IPV is a potentially preventable issue, but its complexity requires the articulation of different sectors (including health systems, education, justice, among others), in different levels (highlighting the key potential role of the primary care level, but connecting to other levels), with collaboration of different actors (such as health professionals, managers, police, etc.) and with different targets (survivors, perpetrators, families, communities, etc.).

Facing this complex scenario, it is significant to recognize the limitations of this review, such as the types of studies included, that do not include all possible methodological approaches conducted in LMIC. Another limitation is the possible diversity of interventions, that can be challenging to be compared and systematised. It could be possible that other relevant studies will be excluded, since this

1
2
3 review includes only studies published in English, Portuguese and Spanish. Another potential
4 limitation may be that funding for rigorous studies of IPV interventions has only been fostered in the
5 past few years, potentially limiting the ability to identify relevant studies in the review time period. In
6 a systematic review, this limitation may also become a study finding, since a dearth of evidence is, in
7 itself, useful to inform the field.

8
9 It is important to mention that the findings of this systematic review will be cautiously interpreted and
10 the conclusions will be presented with parsimony, considering such limitations. This review will only
11 focus in a 'tip of the iceberg', but it can raise questions for future studies with focus, for example, in
12 other levels of care or in other sectors rather than the public health or even including other
13 methodological approaches, such as qualitative studies, which have been extensively reported in
14 LMIC.
15

16 17 **ETHICS AND DISSEMINATION**

18 19 **Ethical issues**

20
21 This systematic review is based on studies previously published and does not include collection of
22 new primary data. Consequently, the host university has stated that is not necessary to obtain ethical
23 clearance.
24

25 26 **Publication Plan**

27 This review will be publicized in conferences (preliminary results) and the final article will be
28 published in a peer-reviewed journal. We intend to publish both the protocol and the systematic
29 review in open access journals, aiming to be accessible to investigators currently engaged in
30 interventions in low-and-middle-income countries. This review affords a voice to researchers in the
31 field of IPV who would otherwise go unheard, and provide greater insights into the range of possible
32 interventions for nations facing comparable issues. It is expected that the final publication can support
33 public systems and policies worldwide.
34

35 36 **Author's contributions**

37 MS conceived the review. SH, BQ, DO and AT assisted on the design of the study protocol. MS and
38 SH drafted the protocol paper and all authors edited the subsequent versions. AT and KH critically
39 revised the methodology. All authors have reviewed and approved the final version of the text. MS is
40 the guarantor of the review.

41 **Funding:** This work was supported by the Brazilian CAPES Foundation which funded a scholarship
42 for postdoctoral studies of the first author [Process number 88881.119273/2016-01]. The funder had
43 no role on this protocol development.
44
45

46
47 **Competing interests:** none
48
49

50 51 **REFERENCES**

- 52
53 1. WHO. Global and regional estimates of violence against women: prevalence and health effects of
54 intimate partner violence and non-partner sexual violence. Geneva: World Health
55 Organization Department of Reproductive Health and Research, London School of Hygiene
56 and Tropical Medicine, South African Medical Research Council., 2013.
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
2. Krug EG, Mercy JA, Dahlberg LL, et al. The world report on violence and health. *Lancet* 2002;360(9339):1083-8. doi: 10.1016/S0140-6736(02)11133-0
 3. Garcia-Moreno C, Jansen HA, Ellsberg M, et al. Prevalence of intimate partner violence: findings from the WHO multi-country study on women's health and domestic violence. *Lancet* 2006;368(9543):1260-9. doi: 10.1016/S0140-6736(06)69523-8
 4. Campbell JC. Health consequences of intimate partner violence. *Lancet* 2002;359(9314):1331-6. doi: 10.1016/S0140-6736(02)08336-8
 5. Coker AL, Davis KE, Arias I, et al. Physical and mental health effects of intimate partner violence for men and women. *Am J Prev Med* 2002;23(4):260-8.
 6. Dutton MA, Green BL, Kaltman SI, et al. Intimate partner violence, PTSD, and adverse health outcomes. *J Interpers Violence* 2006;21(7):955-68. doi: 10.1177/0886260506289178
 7. Sarkar NN. The impact of intimate partner violence on women's reproductive health and pregnancy outcome. *J Obstet Gynaecol* 2008;28(3):266-71. doi: 10.1080/01443610802042415
 8. World Bank Country and Lending Groups. Washington: World Bank, 2017.
 9. UN. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015:31.
 10. Organization WH. Global plan of action to strengthen the role of the health system within a national multisectoral response to address interpersonal violence, in particular against women and girls, and against children. In: research Dfrha, ed. Geneva: WHO, 2016:76.
 11. Signorelli MC, Taft A, Pereira PP. Intimate partner violence against women and healthcare in Australia: charting the scene. *Cien Saude Colet* 2012;17(4):1037-48.
 12. Carvalho G. A saúde pública no Brasil. *Estudos Avançados* 2013;27(78):20. doi: <http://dx.doi.org/10.1590/S0103-40142013000200002>
 13. Aboal-Viñas JL. Salud pública y sistema sanitario. *Gaceta Sanitaria* 2010;4(Supplement 1):7. doi: <https://doi.org/10.1016/j.gaceta.2010.08.003>
 14. Naidoo S. The South African national health insurance: a revolution in health-care delivery! *J Public Health (Oxf)* 2012;34(1):149-50. doi: 10.1093/pubmed/fds008
 15. García-Moreno C, Hegarty K, d'Oliveira AF, et al. The health-systems response to violence against women. *Lancet* 2015;385(9977):1567-79. doi: 10.1016/S0140-6736(14)61837-7 [published Online First: 2014/11/21]
 16. Keleher H. Why primary health care offers a more comprehensive approach to tackling health inequities than primary care. *Australian Journal of Primary Health* 2001;7(2):5.
 17. Care ICoPH. Declaration of Alma-Ata. *WHO Chron* 1978;32(11):428-30.
 18. (APHCRI) APHCRI. What is primary health care? In: (APHCRI) APHCRI, ed. Canberra: Australian Primary Health Care Research Institute (APHCRI), 2009.
 19. Abramsky T, Devries K, Kiss L, et al. Findings from the SASA! Study: a cluster randomized controlled trial to assess the impact of a community mobilization intervention to prevent violence against women and reduce HIV risk in Kampala, Uganda. *BMC Med* 2014;12(1):122. doi: 10.1186/s12916-014-0122-5
 20. Colombini M, Mayhew S, Watts C. Health-sector responses to intimate partner violence in low- and middle-income settings: a review of current models, challenges and opportunities. *Bull World Health Organ* 2008;86(8):635-42.
 21. Bacchus LJ, Colombini M, Contreras Urbina M, et al. Exploring opportunities for coordinated responses to intimate partner violence and child maltreatment in low and middle income countries: a scoping review. *Psychol Health Med* 2017;22(sup1):135-65. doi: 10.1080/13548506.2016.1274410 [published Online First: 2017/02/02]
 22. Bair-Merritt MH, Lewis-O'Connor A, Goel S, et al. Primary care-based interventions for intimate partner violence: a systematic review. *Am J Prev Med* 2014;46(2):188-94. doi: 10.1016/j.amepre.2013.10.001
 23. Bourey C, Williams W, Bernstein EE, et al. Systematic review of structural interventions for intimate partner violence in low- and middle-income countries: organizing evidence for prevention. *BMC Public Health* 2015;15:1165. doi: 10.1186/s12889-015-2460-4 [published Online First: 2015/11/23]
 24. Hegarty K, Tarzia L, Hooker L, et al. Interventions to support recovery after domestic and sexual violence in primary care. *Int Rev Psychiatry* 2016;28(5):519-32. doi:

- 10.1080/09540261.2016.1210103 [published Online First: 2016/08/09]
25. Taft AJ, Hooker L, Humphreys C, et al. Maternal and child health nurse screening and care for mothers experiencing domestic violence (MOVE): a cluster randomised trial. *BMC Med* 2015;13:150. doi: 10.1186/s12916-015-0375-7 [published Online First: 2015/06/25]
 26. Signorelli MC, Auad D, Pereira PP. Domestic violence against women and professional intervention in primary healthcare: an ethnographic study in Matinhos, Paraná State, Brazil. *Cad Saude Publica* 2013;29(6):1230-40.
 27. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. *Milbank Q* 2005;83(3):457-502. doi: 10.1111/j.1468-0009.2005.00409.x
 28. Kruk ME, Porignon D, Rockers PC, et al. The contribution of primary care to health and health systems in low- and middle-income countries: a critical review of major primary care initiatives. *Soc Sci Med* 2010;70(6):904-11. doi: 10.1016/j.socscimed.2009.11.025 [published Online First: 2010/01/19]
 29. Chan M. Ten years in public health, 2007–2017. In: Organization WH, ed. Geneva: World Health Organization, 2017:152.
 30. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/01]
 31. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ* 2015;349:g7647. [published Online First: 2015/01/02]
 32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62(10):1006-12. doi: 10.1016/j.jclinepi.2009.06.005 [published Online First: 2009/07/23]
 33. Higgins J, Green S, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. West Sussex: The Cochrane Collaboration and John Wiley & Sons, 2008.
 34. Blankenship KM, Friedman SR, Dworkin S, et al. Structural interventions: concepts, challenges and opportunities for research. *J Urban Health* 2006;83(1):59-72. doi: 10.1007/s11524-005-9007-4
 35. WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Appendix 1 Definitions of health-care settings and other related terms. Geneva: World Health Organization, 2009.
 36. Hegarty K, Fracgp, Bush R, et al. The composite abuse scale: further development and assessment of reliability and validity of a multidimensional partner abuse measure in clinical settings. *Violence Vict* 2005;20(5):529-47.
 37. Campbell DW, Campbell J, King C, et al. The reliability and factor structure of the index of spouse abuse with African-American women. *Violence Vict* 1994;9(3):259-74.
 38. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. *Psychol Med* 1979;9(1):139-45.
 39. Eaton W, Smith C, Ybarra M, et al. Center for Epidemiologic Studies Depression Scale: review and revision (CESD and CESD-R). In: Maruish M, ed. *The Use of Psychological Testing for Treatment Planning and Outcomes Assessment*. 3 ed. Mahwah, NJ: Lawrence Erlbaum Associates, Inc 2004.
 40. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary care. *Behav Res Ther* 2005;43(5):585-94. doi: 10.1016/j.brat.2004.04.005
 41. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.
 42. Campbell JC. Nursing assessment for risk of homicide with battered women. *ANS Adv Nurs Sci* 1986;8(4):36-51.
 43. Landgraf J, Abetz L, Ware J. *The Child Health Questionnaire (CHQ) user's manual*. 1st ed. ed. Boston: TheHealth Institute, New England Medical Centre, 1996.
 44. Ayala Quintanilla BP, Taft A, McDonald S, et al. Social determinants and maternal exposure to intimate partner violence of obstetric patients with severe maternal morbidity in the intensive care unit: a systematic review protocol. *BMJ Open* 2016;6(11):e013270. doi:

- 1
2
3 10.1136/bmjopen-2016-013270 [published Online First: 2016/11/28]
4 45. Schünemann HJ, Schünemann AH, Oxman AD, et al. Grading quality of evidence and strength of
5 recommendations for diagnostic tests and strategies. *BMJ* 2008;336(7653):1106-10. doi:
6 10.1136/bmj.39500.677199.AE
7 46. Pandis N, Fedorowicz Z. The international EQUATOR network: enhancing the quality and
8 transparency of health care research. *J Appl Oral Sci* 2011;19(5)
9 47. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk
10 of bias in randomised trials. *BMJ* 2011;343:d5928. [published Online First: 2011/10/18]
11 48. Slim K, Nini E, Forestier D, et al. Methodological index for non-randomized studies (minors):
12 development and validation of a new instrument. *ANZ J Surg* 2003;73(9):712-6.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1 - PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Page number
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	Not an update
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	PROSPERO CRD420170692613
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1-2
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	12
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	Not applicable
Support:			
Sources	5a	Indicate sources of financial or other support for the review	12
Sponsor	5b	Provide name for the review funder and/or sponsor	12
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	12
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	3-5
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	5
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6-8
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	7

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	Appendix 2
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	9
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	9 and Appendix 4
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	7
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	9
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	10
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ)	10
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	Not applicable
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	10-11
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	Not applicable
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	9-10

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix 2 - General Search Strategy

1. ('primary health care*' or 'primary care*' or 'primary health*' or 'primary health care interven*' or 'health* manag*' or 'care manag*' or 'primary health interven*' or 'prevent* program*' or 'prevent* interven*' or 'early interven*' or 'primary health*' or 'strateg*' or 'health promot*' or 'comprehensive health*' or 'community health*' or 'famil* health*' or 'public health*' or 'health* system*' or 'health* worker*' or 'health* profession*' or 'health* polic*' or 'antenatal car*' or 'antenatal clinic*' or 'basic health*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

2. Primary Health Care/ or Public Health/ or Health Policy/ or Health Promotion/ or Health Personnel/ or Developing Countries/

3. 1 {or/and} 2

4. ('partner violen*' or 'partner abus*' or 'spouse violen*' or 'spouse abus*' or 'partner harm*' or 'violen* against wom*' or 'battered women' or 'dating violen*' or 'dating abus*' or 'gender based violen*' or 'gender based abus*').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

5. Intimate Partner Violence/ or Battered Women/

6. 4 {or/and} 5

7. ('low* middle* incom* countr*' OR 'low* incom* countr*' OR 'middle* incom* countr*' OR 'underdevelop* countr*' OR 'developing countr*' OR 'third* world countr*' OR 'low* middle* income* nation*' OR 'third*world* nation*' OR 'underdevelop* nation*' OR 'less* developed nation*' OR 'low* income nation*' OR 'developing nation*' OR 'least* developed countr*' OR 'emerg* countr*' OR 'less-developed countr*' OR 'developing world*' OR 'undeveloped world*' OR 'emerg* world' OR 'Latin* America*' OR 'Central* America*' OR 'Caribbean' OR 'South* America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle* East*' OR 'Latin* America*' OR 'Central America*' OR 'South America*' OR 'Africa*' OR 'Asia*' OR 'Pacific' OR 'Middle East*' OR 'Afghanistan' OR 'Albania' OR 'Algeria' OR 'American Samoa' OR 'Angola' OR 'Argentina' OR 'Armenia' OR 'Azerbaijan' OR 'Bangladesh' OR 'Belarus' OR 'Belize' OR 'Benin' OR 'Bhutan' OR 'Bolivia' OR 'Bosnia*Herzegovina' OR 'Botswana' OR 'Brazil' OR 'Bulgaria' OR 'Burkina Faso' OR 'Burundi' OR 'Cabo Verde' OR 'Cambodia' OR 'Cameroon' OR 'Central African Republic' OR 'Chad' OR 'China' OR 'Colombia' OR 'Comoros' OR 'Congo, Dem* Rep*' OR 'Congo, Rep*' OR 'Costa Rica' OR 'Cote d'Ivoire' OR 'Cuba' OR 'Djibouti' OR 'Dominica' OR 'Dominican Republic' OR 'Ecuador' OR 'Egypt' OR 'El Salvador' OR 'Equatorial Guinea' OR 'Eritrea' OR 'Ethiopia' OR 'Fiji' OR 'Gabon' OR 'Gambia' OR 'Georgia' OR 'Ghana' OR 'Grenada' OR 'Guatemala' OR 'Guinea' OR 'Guinea-Bissau' OR 'Guyana' OR 'Haiti' OR 'Honduras' OR 'India' OR 'Indonesia' OR 'Iran' OR 'Iraq' OR 'Jamaica' OR 'Jordan' OR 'Kazakhstan' OR 'Kenya' OR 'Kiribati' OR 'Korea, Dem* People's Rep*' OR 'North Korea' OR 'Kosovo' OR 'Kyrgyz' OR 'Lao' OR 'Lebanon' OR 'Lesotho' OR 'Liberia' OR 'Libya' OR 'Macedonia' OR 'Madagascar' OR 'Malawi' OR 'Malaysia' OR 'Maldives' OR 'Mali' OR 'Marshall Islands' OR 'Mauritania' OR 'Mauritius' OR Mexico' OR 'Micronesia' OR 'Moldova' OR 'Mongolia' OR 'Montenegro' OR 'Morocco' OR 'Mozambique' OR 'Myanmar' OR 'Namibia' OR 'Nepal' OR 'Nicaragua' OR Niger' OR 'Nigeria' OR 'Pakistan' OR 'Palau' OR 'Palestine' OR 'Panama' OR 'Papua New Guinea' OR 'Paraguay' OR 'Peru' OR 'Philippines' OR 'Romania' OR 'Russian Federation' OR 'Russia' OR 'Rwanda' OR 'Samoa' OR 'Sao Tome and Principe' OR 'Senegal' OR 'Serbia' OR 'Sierra Leone' OR 'Solomon Islands' OR 'Somalia' OR 'South Africa' OR 'South Sudan' OR 'Sri Lanka' OR 'St. Lucia' OR 'St. Vincent and the Grenadines' OR 'Sudan' OR 'Suriname' OR 'Swaziland' OR 'Syrian Arab Republic' OR 'Syria' OR 'Tajikistan' OR 'Tanzania' OR 'Thailand' OR 'Timor-Leste' OR 'East Timor' OR 'Togo' OR 'Tonga' OR 'Tunisia' OR 'Turkey' OR 'Turkmenistan' OR 'Tuvalu' OR 'Uganda' OR 'Ukraine' OR 'Uzbekistan' OR 'Vanuatu' OR 'Venezuela' OR 'Vietnam' OR 'West Bank* Gaza' OR 'Yemen' OR 'Zambia' OR 'Zimbabwe').mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word,

rare disease supplementary concept word, unique identifier, synonyms]

8. Developing countries/ OR Argentina/ OR Bolivia/ OR Brazil/ OR Colombia/ OR Ecuador/ OR Guyana/ OR Paraguay/ OR Peru/ OR Suriname/ OR Venezuela/ OR exp Latin America/ OR exp Caribbean Region/ OR exp Central America/ OR exp Africa/ OR esp Central Asia/ OR exp Northern Asia/ OR Cambodia/ OR Timor-Leste/ OR Indonesia/ OR Laos/ OR Malaysia/ OR Myanmar/ OR Philippines/ OR Thailand/ OR Vietnan/ OR Bangladesh/ OR Buthan/ OR exp India/ OR Nepal/ OR Pakistan/ OR Sri Lanka/ OR Afghanistan/ OR Iran/ OR Iraq/ OR Jordan/ OR Lebanon/ OR Syria/ OR Turkey/ OR Yemen/ OR exp China/ OR Mongolia/ OR Democratic People’s Republic of Korea/ OR Balkan Peninsula/ OR Albania/ OR Bosnia and Herzegovina/ OR Bulgaria/ OR Kosovo/ OR Macedonia/ OR Moldova/ OR Montenegro/ OR exp Republic of Belarus OR Romania/ OR exp Russia/ OR Serbia/ OR Ukraine/ OR exp Transcaucasia/ OR Comoros/ OR Madagascar/ OR Mauritius/ OR Indonesia/ OR Fiji/ OR Papua New Guinea/ OR Vanuatu/ OR Palau/ OR exp Samoa/ OR Tonga/ OR Cuba/ OR Dominica/ OR Dominican Republic/ OR Grenada/ OR Haiti/ OR Jamaica/ OR St. Lucia/ OR St. Vincent and the Grenadines/

9. 7 {or/and} 8

10. 3 and 6 and 9

11. Limit 10 to (full text and yr="2007 -Current" and (English or Portuguese or Spanish))

Search	Free text words - Portuguese (MeSH terms only available in English)
#1	<p>“atenção primár* saúde” OR “cuidado* primár*” OR “saúde primár*” OR “gestão* saúde” OR “manej* saúde” OR “interven* saúde* primár*” OR “program* preven*” OR “interven* preven*” OR “interven* precoce*” OR “estratégi* saúde primár*” OR “promoç* d* saúde” OR “saúde integral*” OR “saúde* comuni*” OR “saúde* família*” OR “saúde públic*” OR “sistema* saúde*” OR “trabalhador* saúde” OR “agente* saúde” OR “profissiona* saúde” OR “polític* saúde” OR “cuidado* pré-nata*” OR “ambulator* pré-nata*” OR “saúde básic*” OR “atenç* básic*” OR “centro* saúde” OR “posto* saúde” OR “unidade* saúde”</p>
#2	<p>“violen* parceir*” OR “abus* parceir*” OR “violen* conjug*” OR “abus* conjug*” OR “agress* parceir*” OR “violen* contra* mulher*” OR “mulher* espancada*” OR “violen* namor*” OR “abus* namor*” OR “violen* gênero” OR “abus* gênero”</p>
#3	<p>“país* renda baixa* média*” OR “país* baixa* média* renda*” OR “país* baixa* renda*” OR “país* renda* média” OR “país* subdesenvolv*” OR “país* em desenvolvimento” OR “país* terceiro mundo” OR “naç* renda baixa* média*” OR “naç* terceiro mundo” OR “naç* subdesenvolv*” OR “naç* menos desenvolvid*” OR “naç* baix* desenvolv*” OR “naç* em desenvolvimento” OR “país* menos desenvolvid*” OR “país* emergente*” OR “país* pobre*” OR “naç* pobre*” OR “mundo em desenvolvimento” OR “mundo subdesenvolvido” OR “mundo emergente” OR “naç* emergente* OR “América Latin*” OR "América Central" OR "América do Sul" OR “Carib*” OR “África*” OR “Ásia*” OR “Pacífico*” OR “Oceania” OR "Oriente Médio" OR "Afeganistão" OR "Albânia" OR "Argélia" OR "Samoa Americana" OR "Angola" OR "Argentina" OR "Armênia" OR "Azerbaijão" OR "Bangladesh" OR "Bielorrússia" OR "Belize" OR "Benin" OR "Butão" OR "Bolívia" OR "Bósnia* Herzegovina" OR "Botswana" OR "Brasil" OR "Bulgária" OR “Burkina Faso” OR "Burundi" OR "Cabo Verde" OR "Camboja" OR "Camarões" OR "República Centro-Africana" OR "Chade" OR "China" OR "Colômbia" OR "Comores" OR "Congo, Dem* Rep*” OR "Congo, Rep*” OR "Costa Rica" OR "Costa do Marfim" OR "Cuba" OR "Djibouti” OR</p>


<p>"Dominica" OR "República Dominicana" OR "Equador" OR "Egito" OR "El Salvador" OR "Guiné Equatorial" OR "Eritreia" OR "Etiópia" OR "Fiji" OR "Gabão" OR "Gâmbia" OR "Geórgia" OR "Gana" OR "Granada" OR "Guatemala" OR "Guiné" OR "Guiné-Bissau" OR "Guiana" OR "Haiti" OR "Honduras" OR "Índia" OR "Indonésia" OR "Irã" OR "Iraque" OR "Jamaica" OR "Jordânia" OR "Cazaquistão" OR "Quênia" OR "Kiribati" OR "Coréia, Rep* Dem*" OR "Coréia do Norte" OR "Kosovo" OR "Quirguistão" OR "Laos" OR "Líbano" OR "Lesoto" OR "Libéria" OR "Líbia" OR "Macedônia" OR "Madagascar" OR "Malawi" OR "Malásia" OR "Maldivas" OR "Mali" OR "Ilhas Marshall" OR "Mauritânia" OR "Mauríci*" OR "México" OR "Micronésia" OR "Moldávia" OR "Mongólia" OR "Montenegro" OR "Marrocos" OR "Moçambique" OR "Mianmar" OR "Namíbia" OR "Nepal" OR "Nicarágua" OR Níger " OR "Nigéria" OR "Paquistão" OR "Palau" OR "Panamá" OR "Papua Nova Guiné" OR "Paraguai" OR "Peru" OR "Filipinas" OR "Romênia" OR "Federação Russa" OR "Rússia" OR "Ruanda" OR "Samoa" OR "São Tomé e Príncipe" OR "Senegal" OR "Sérvia" OR "Serra Leoa" OR "Ilhas Salomão" OR "Somália" OR "África do Sul" OR "Sudão do Sul" OR "Sri Lanka" OR "St. Lucia" OR "São. Vincente e Granadinas" OR "Sudão" OR "Suriname" OR "Suazilândia" OR "República Árabe da Síria" OR "Síria" OR "Tajiquistão" OR "Tanzânia" OR "Tailândia" OR "Timor-Leste" OR "Timor* Leste" OR "Togo" OR "Tonga" OR "Tunísia" OR "Turquia" OR "Turcomenistão" OR "Tuvalu" OR "Uganda" OR "Ucrânia" OR "Uzbequistão" OR "Vanuatu" OR "Venezuela" OR "Vietn*" OR "Cisjordânia" OR "Gaza" OR "Palestina" OR "Iêmen" OR "Zâmbia" OR "Zimbábue"</p>

Search	Free text words - Spanish (MeSH terms only available in English)
#1	<p>“atenci* primar* salud” OR “atenci* primar*” OR “cuidado* primar*” OR “salud primar*” OR “gestion* salud” OR “manej* salud” OR “interven* primar* salud*” OR “program* OR interven*” OR “interven* tempran*” OR “estrateg* salud primar*” OR “promoc* salud” OR “salud integral*” OR “salud* comuni*” OR “salud* famili*” OR “salud public*” OR “sistema* salud” OR “trabajad* salud” OR “agente* salud” OR “profession* salud” OR “politic* salud” OR “cuidado prenatal*” OR “clínica* prenatal*” OR “salud basic*” OR “atenci* basic*” OR “primer nivel de atención” OR “centro* de salud” OR “puesto* de salud” OR “posta* médica*”</p>
#2	<p>“violen* pareja*” OR “abuso* pareja*” OR “violencia conyug*” OR “abuso conyug*” OR “daño* pareja*” OR “violen* contra la* mujer*” OR “abus* contra la* mujer*” OR “mujer* golpeada*” OR “mujer* maltratada*” OR “violen* contra la* enamora*” OR “abus* contra la* enamora*” OR “violencia de género” OR “abuso de género” OR “violencia de* compañer* íntim*” OR “mujer* violentada*”</p>
#3	<p>“país* con ingreso mediano* bajo*” OR “país* con ingreso bajo* OR “país* subdesarrollado*” OR “país* en desarrollo*” OR “país* tercer mundo” OR “nacion* con ingreso mediano* bajo*” OR “nacion* del tercer mundo” OR “nacion* subdesarrollada*” OR “nacion* menos desarroll*” OR “nacion* con bajo desarroll*” OR “nacion* en desarrollo” OR “país* menos desarroll*” OR “país* menos desarroll*” OR “país* emergente*” OR “nacion* emergente*” OR “mundo emergente” OR “mundo subdesarrollado” OR “país* en vías de desarrollo” OR “Caribe” OR “América Latina*” OR “América del Sur” OR “Sudamérica” “África*” OR “Asia*” OR “Pacífico” OR “Oriente Medio” OR “Afganistán” OR “Albania” OR “Argelia” OR “Angola” OR “Argentina” OR “Samoa Americana” OR “Armenia” OR “Azerbaiyán” OR “Bangladesh” OR “Bielorrusia” OR “Belice” OR “Benin” OR “Bolivia” OR “Bosnia* Herzegovina” OR “Botswana” OR “Brasil” OR “Bulgaria” OR “Burkina Faso” OR “Burundi” OR “Bhutan”</p>

<p>OR "Cabo Verde" OR "Camboya" OR "Camerún" OR "República Centroafricana" OR "Chad" OR "China" OR "Costa Rica" OR "Costa de Marfil" OR "Cuba" OR "Djibouti" OR "Dominica" OR "Costa Rica" OR "Colombia" OR "Comoras" OR "Congo, Rep*" OR "República Dominicana" OR "Ecuador" OR "Egipto" OR "El Salvador" OR "Guinea Ecuatorial" OR "Eritrea" OR "Etiopía" OR "Fiji" OR "Gabón" OR "Georgia" OR "Gambia" OR "Ghana" OR "Grenada" OR "Guatemala" OR "Guinea" OR "Guinea-Bissau" OR "Guyana" OR "Haití" OR "Honduras" OR "India" OR "Indonesia" OR "Iran" OR "Irak" OR "Jamaica" OR "Jordania" OR "Kazajstán" OR "Kenia" OR "Kiribati" OR "Corea, República Democrática" OR "Corea del Norte" OR "Kosovo" OR "Laos" OR "Líbano" OR "Lesotho" OR "Liberia" OR "Libia" OR "Macedonia" OR "Madagascar" OR "Malawi" OR "Malasia" OR "Maldivas" OR "Mali" OR "Islas Marshall" OR "Mauritania" OR "Maurici*" OR "México" OR "Micronesia" OR "Moldavia" OR "Mongolia" OR "Montenegro" OR "Marruecos" OR "Mozambique" OR "Myanmar" OR "Namibia" OR "Nepal" OR "Nicaragua" OR "Níger" OR "Nigeria" OR "Pakistán" OR "Palau" OR "Panamá" OR "Papúa Nueva Guinea" OR "Paraguay" OR "Perú" OR "Filipinas" OR "Rumania" OR "Rusia" OR "Rwanda" OR "Samoa" OR "Santo Tomé y Príncipe" OR "Senegal" OR "Serbia" OR "Sierra Leona" OR "Somalia" OR "Sudáfrica" OR "Sudán del Sur" OR "Sri Lanka" OR "St. Lucia" OR "Siria" OR "Tayikistán" OR "Tanzania" OR "Tailandia" OR "Timor Oriental" OR "República Democrática del Congo" OR "Tonga" OR "Túnez" OR "Turquía" OR "Turkmenistán" OR "Tuvalu" OR "Uganda" OR "Ucrania" OR "Uzbekistán" OR "Vanuatu" OR "Venezuela" OR "Vietnam" OR "Cisjordania*" OR "Gaza" OR "Palestina" OR "Yemen" OR "Zambia" OR "Zimbabwe"</p>
--

This search strategy can be adapted and modified according to each electronic database.

Appendix 3 -PRISMA Flow Diagram: flow of information through different phases of a systematic review



Source: Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097 doi:10.1371/journal.pmed.1000097 [published Online: 21 July 2009].

Appendix 4 - Data Items

1. General Information and characteristics of the studies

- a. Author's name
- b. Journal
- c. Year of publication
- d. Country of the intervention
- e. Context (urban/rural)
- f. Type of service/setting
- g. Participants (e.g. workers, users - victims, family members, perpetrators)

2. Methodology

- a. Study design
- b. Type of intervention
- c. Sample/number of participants
- d. Year(s) when intervention was conducted
- e. Data collection
- f. Measures
- g. Analysis
- h. Ethics clearance

3. Impacts and outcomes of the intervention for survivors:

- a. IPV rates
- b. health (e.g. physical, mental)
- c. safety (e.g. safety plans)
- d. wellbeing (e.g. quality of life)
- e. children (e.g. children's health and wellbeing)
- f. Other Impacts and outcomes (if described)
- g. Barriers and facilitators for survivors (if investigated)

4. Impacts and outcomes of the intervention for PHC workers' practices:

- a. Types of workers (e.g. nurses, community health workers, receptionists)
- b. Worker's role in the intervention
- c. Measures of impacts and outcomes concerned to workers
- d. Barriers and facilitators for workers (if described)

5. Role of the PHC services and public health systems to improve survivors' healthcare:

- a. Measures of impacts and outcomes of the intervention for services/systems
- b. Impacts and outcomes of the intervention for policies and organizational structure
- c. Articulation with other levels of care in the healthcare system (e.g. hospital, emergency, etc.)
- d. Articulation with other sectors beyond public health (e.g. police, justice, housing, etc.)
- e. Costs
- f. Sustainability
- g. Barriers and facilitators for services/systems (if described)

6. Other relevant information